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Resumo
Enquadramento
Cerca de 2 a 8% dos indivíduos acima dos 60 anos de idade sofrem de alguma 
forma de Demência, de entre as quais a Doença de Alzheimer (DA) é a mais 
comum. Até ao presente, a doença não tem cura, exercendo uma enorme pressão 
sobre os custos dos serviços sociais de saúde de cada país - é a sexta maior 
causa de morte nos Estados Unidos e representa mais da metade de todos os 
casos de demência, que se estimam vir quadruplicar nas próximas quatro 
décadas.
Objectivos
A Acupunctura Craniana de Heidelberg (ACH) é um novo sistema somatotópico de 
acupunctura, tendo por base a existência de correlações entre pontos específicos 
localizados no escalpe, funções fisiológicas e regiões anatómicas. Com suporte 
em experiências anteriores, propomos desenvolver um protocolo de estudo, 
envolvendo o tratamento de pacientes portadores da Doença de Alzheimer, 
através da ACH, avaliando o potencial benefício em termos da evolução da função 
cognitiva, medida através do recurso a testes psicométricos, nomeadamente a 
Avaliação Breve do Estado Mental (ABEM) e à vertente cognitiva da Escala de 
Avaliação da Doença de Alzheimer (EADA).
Propomos no final uma abordagem metodológica para comparar a eficácia da 
terapia combinada (ACH + terapia farmacológica) vs terapia farmacológica, na 
função cognitiva de doentes de Alzheimer.
Métodos
Depois de obtido parecer positivo por parte da Comissão de Ética do ICBAS-UP, 
foram contactados catorze pacientes diagnosticados com DA por um neurologista 
independente. Seis desses sujeitos (idade média de 78.5 anos), aceitaram o 
convite para fazer parte de um estudo preliminar e, após o consentimento 
informado, foram aplicadas e retidas por um período de 3 dias, sete agulhas 
permanentes (gold) nos apelidados sete chakras. Como parte dos critérios de 
inclusão, foi solicitado ao seu médico responsável a não alteração da medicação 
durante o período de experiência.
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Resultados
Após administração da ACH, verificámos melhorias nos resultados de testes em 
cinco dos seis pacientes que incorporaram o estudo. No que respeita à ABEM o 
aumento médio foi de 3,83 pontos (4.36dp) e na EADA-cog, a melhoria está 
reflectida na redução média verificada de 4,67 pontos (5.72dp). Não foram 
observadas diferenças estatisticamente significativas quando comparadas as 
médias obtidas antes e depois da condição de tratamento. Os dados permitiram 
ainda a estimativa do tamanho da amostra, que neste caso deverá ser n>289.
Discussão
Apesar da ausência de significância estatística, o que em nossa opinião se fica a 
dever ao reduzido tamanho da amostra e aos elevados desvios-padrão verificados 
(algo expectável para a patologia), no presente estudo foram observadas 
melhorias individuais e incrementos médios impressionantes para ambos os 
testes. 
A Acupunctura Craniana de Heidelberg parece promissora na reversão do déficit 
cognitivo dos pacientes com DA. O eventual mecanismo de acção da ACH na DA 
poderá estar relacionado com o aumento da microcirculação em algumas zonas 
cerebrais, no entanto, este raciocínio é puramente especulativo e deverá ser 
objecto de investigações futuras. Após análise estatística e qualitativa dos dados, 
propomos uma metodologia para um futuro ensaio clínico.
Keywords: Acupunctura Craniana de Heidelberg; Doença de Alzheimer; Avaliação 
Breve do Estado Mental; Escala de Avaliação da Doença de Alzheimer - sub-escala 
cognitiva; Acupunctura; Medicina Tradicional Chinesa; micro Acupunctura
Este texto é escrito de acordo com o antigo acordo ortográfico.
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Abstract
Background
In each country 2 to 8% of the individuals above 60 years old are expected to 
suffer from any form of the dementia, from which Alzheimer’s Disease is the 
most common form. This medical condition for which there is still no cure, puts a 
considerable amount of pressure on national health care systems facing 
immensely huge health care costs. The disease is already the sixth leading cause 
of death in the United States and it represents more than half of all Dementia 
cases, which are expected to quadruple over the next four decades.
Objectives
Heidelberg Scalp Acupuncture (HSA) is a novel somatotopic system of 
Acupuncture developed on the basis of existing correlations between specific 
skull acupoints, physiological functions and anatomical regions. Due to some 
positive personal experience with this technique, we are interested in finding 
whether it is possible to develop a study protocol to treat Alzheimer’s Disease by 
HSA, and to measure the potential clinical outcome using psychometric tests - the 
Mini Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale 
- cognitive subscale (ADAS-cog).
We further propose a methodological approach to compare the efficacy of a 
combined therapy (HSA and pharmacological treatment) versus pharmacological 
treatment alone, on the cognitive function of AD patients.
Methods
After obtaining positive feedback from the ICBAS-UP Ethical Committee, fourteen 
patients diagnosed with AD by an independent Neurologist were contacted. Six of 
these subjects (mean age 78.5 years), showed willingness to be part of a 
preliminary study and after informed consent, HSA was applied. Permanent scalp 
acupuncture gold needles were retained for a three day period in the so called 
seven chakras with no change in the patients medication occurring during the 
test period (part of the eligibility criteria).
Results
Out of the six patients that took part in the experiment, five have shown better 
values in both tests after HSA. Regarding MMSE, average increase was 3.83 points 
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(4.36sd) and on ADAS-cog, improvement was reflected by an average decrease of 
4.67 points (5.72sd). No statistical differences were found before and after the 
treatment condition. The data further allowed the estimation of the sample size, 
which in this case should be n>289.
Discussion
Despite the absence of statistical significance, which in our opinion is due to the 
small sample size and high standard deviations (which is expected in this 
disease), we measured impressive individual and average improvements in MMSE 
and ADAS-cog. 
Heidelberg Scalp Acupuncture showed promising results on the reversion of the 
cognitive deficit felt by AD patients. The mechanism by which this potential effect 
may take place could be an increase microcirculation within certain areas of the 
brain, although this remains speculative. After statistical analysis and scrutiny of 
recovered insights, a methodology for a future clinical trial is proposed.
Keywords: Heidelberg Scalp Acupuncture; Alzheimer’s Disease; Mini Mental State 
Examination; Alzheimer’s Disease Assessment Scale - cognitive subscale; 
Acupuncture; Traditional Chinese Medicine; Micro Acupuncture
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In a competitive world, survival of the fittest is key to accomplishment. Cognitive 
function plays a paramount role in the quality-of-life of the individual, younger or 
older. In younger people, as part of the learning process, the brain is 
continuously being stimulated and requested as a fundamental asset in the 
growing up, evolutionary process, and in older people, because as one grow old, 
brain function decreases and this progressive reduction contributes to an array of 
impairments that in term, may lead to increased levels of morbidity and even 
mortality.
One of the immediate consequences of this lack of function, can be observed on 
the degree of dependency that patients suffering from dementia have of another 
individual for the everyday tasks, leading to new social, medical and personal 
needs that didn’t exist before the disease. 
Of gradual onset, dementias are one of the major causes of disability and lack of 
social independency among elderly people (Alzheimer’s Association 2014).
WHOi estimates that 35.6 million people worldwide suffer from dementia and that 
there are 7.7 million new cases each year, with projections to double this value 
every 20 years. 
In each country 2 to 8% of the individuals above 60 years old are expected to 
suffer from any form of the dementia, from which Alzheimer is the most 
common, reaching to 60 to 80% of all dementia cases (Alzheimer's Association 
2012, Alzheimer’s Association 2013, Alzheimer’s Association 2014); (OECD 
2013).
In the United States of America, where estimations point to 469.000 new cases 
this year alone, Alzheimer’s Disease is the 6th leading cause of death - one in 
every nine individuals aged 65 and plus have ADii and every 67 seconds a new 
case is diagnosed, time that is expected to be reduced to 33 seconds by mid-
century (Alzheimer's Association 2012, Alzheimer’s Association 2013, 
Alzheimer’s Association 2014).
When it comes to OECDiii (2013) state members, reporting to 2009, an estimated 
14 million people over 60 years old suffer from dementia. 
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i WHO - World Health Organization
ii AD - Alzheimer’s Disease
iii Organization for Economic Co-operation and Development 
Portuguese Alzheimer’s Association (2014) reckons that a total of 90.000 people 
suffer from AD in this country. Acknowledging the impact of this matter within 
the nation’s health status, the portuguese Solidarity Minister previews for 2015, 
the conclusion of one of the largest and more expensive studies in the nation to 
this day, (requiring a total of €3,6 million), with the objective to correctly identify 
Dementia cases and reeducate specialized technicians to cope with the disease 
(Sapo Saúde 2014).
The prevalence of the disease is higher in women than in men, with almost two 
thirds of patients with AD belonging to the female gender, what might be 
explained by longer life-expectancy rates of women. Some authors however 
(Paganini-Hill and Henderson 1994), suggest a relation between estrogen loss 
related to menopause, as a possible explanation to elevated rates of development 
of AD in women. Also when observing educational levels, it seems that people 
with fewer educational level may be in higher risk to develop dementias 
(Alzheimer’s Association 2014).
Disease Costs
“AD is one of the costliest chronic disease to society”
(Alzheimer’s Association 2014)
Up to date, there is no cure for AD, and the long duration of the illness from 
diagnosis to death - an average of six years - contributes significantly to its public 
health relevance (Ganguli, Dodge et al. 2005).
The economical impact is not restricted to families and relatives of affected 
individuals, but also concerns national health systems, morally and legally 
obligated to provide solutions to deal with the effects of the disease.
Alone in the USA, the direct expenditures of the nation attributed to Alzheimer’s 
Disease, estimated by the Alzheimer's Association (2014), reached $214 billion in 
2014, ($150 billion covered by Medicare and Medicaid National health systems), 
costs that according to Hurd et al. (2013), will yet increase to an hopping $1,2 
trillion in 2050.  
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As AD progresses, patients tend to loose space and time references. There is a 
gradual loss of cognitive function and memory, often confounded by the normal 
progression of the aging process. 
Patients become dependant of others to perform their daily activities and routines 
and personality and behavioral disturbances make it a challenge to act according 
to community and social standards. Once a kind grandmother or grandfather, 
husband or wife, mother or father, the AD patient gradually becomes a 
stigmatized, unrecognizable human being, surrounded by unfamiliar faces. 
Caring for these patients rapidly becomes a full time job. A 24-7, 365 days a year 
task, mainly performed by non-paid family members. Despite the fact that 80% of 
total care among AD patients is reported as being informal and therefore non 
paid, these caregivers are left with a huge invoice - the oblivious human cost of 
the disease. 
In a study with the objective to describe the mental state and needs of Dementia 
and Alzheimer’s Disease caregivers in Portugal, França (2010) found that these 
group of people tend to suffer from a higher degree of symptomatology on their 
psychopathological profile, when compared to the general population, showing 
high prevalence of Anxiety levels, Depression and other mental disbalances. 
Common sentences within families affected by the disease include the negative, 
cold blunted, “nothing can be done”, where hopeless is frequently the prevailing 
sentiment, slowly and subtly draining emotions away.
AD cannot be considered just a family problem, but actually, also a social 
challenge. Worldwide population is becoming older by the second. While scientific  
advances contributes to increase life expectancy rates, the current social and 
economic conditions do not favor families with several descendants like once did. 
Demographic pyramids are becoming inverted, and the world’s 7,6% of 
individuals aged 65 or older in 2010 are expected to turn into 22,3% by 2100. 
This in all, makes it crucial to find effective means to invert the course of this 
hungry resource consuming disease and renew the hope of these patients, their 
families and the whole community. 
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Since there is no cure for AD and conventional medical treatment remains limited, we want to study  
whether additional treatments offered by complementary therapies, such as Traditional Chinese 
Medicine, may represent an increased value for patients.
Acupuncture is embedded in Tradicional Chinese Medicine - one of the oldest known documented 
World Medicines.
Some doubts concerning its mechanism of action and effectiveness still prevail to these days. The 
number of studies on the subject is yet scarce, and generally methodological issues prevent clear, 
non dubious conclusions (Hurd, Martorell et al. 2013). Nevertheless there has been some evidence of 
positive effects of its usage on the treatment of Dementia and AD.
Craniopuncture or Scalp Acupuncture (SA) by its turn, can be observed as a derived form of 
acupuncture. Recent unpublished work by prominent german physician and TCM Professor, Greten, 
using the so-called Heidelberg Scalp Acupuncture (HSA) methodology on Alzheimer’s Disease 
patients seems promising, although scientific evidence to support his findings is needed. 
It is our belief that HSA might have a positive effect on reducing cognitive loss in Alzheimer’s 
patients, thus improving these patients quality of life. Taking this into account, we will try to 
compare the cognitive changes observed in patients subjected to HSA plus pharmacological therapy 
vs those obtained when pharmacological therapy is used alone.
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2ALZHEIMER’S DISEASE
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2.1
DIAGNOSIS
The diagnostic criteria for Alzheimer’s Disease was initially established by 
Mckhann and his peers (1984) on a NINCDS-ADRDAi report. These authors 
categorized AD into Probable AD, Possible AD and Definite AD (table 1).
Probable 
Alzheimer’s 
Disease
All of the following must be present:
-Dementia established by examination and documented by objective testing 
-Impairment in memory and at least one other cognitive function (e.g., language 
or perception)
-Progressive worsening of memory and at least one other cognitive function
-No disturbance in consciousness
-Onset between 40 and 90 years of age
-Absence of another brain disorder or systemic disease that might cause 
dementia
In addition, the diagnosis may be supported by one or more of the following:
-Loss of motor skills
-Diminished independence in activities of daily living and altered patterns of 
behaviour
-Family history of similar disorder
-Laboratory results consistent with the diagnosis (e.g., cerebral atrophy on 
computed tomography)
Possible 
Alzheimer’s 
Disease
Fulfillment of the above criteria with variation in the onset of symptoms or 
manifestations or in clinical course; or a single, but gradually progressive, 
cognitive impairment without an identifiable cause
Another brain disorder or systemic disease that is sufficient to produce 
dementia, but that is not considered to be the underlying cause of the dementia 
in the patient
Definite 
Alzheimer’s 
Disease
Fulfilment of the above clinical criteria and histologic evidence of Alzheimer’s 
disease based on examination of brain tissue obtained at biopsy or autopsy
Table 1 - Alzheimer’s Disease categorization according to Mckhann et al. (1984)
AD is therefore defined as a special form of Dementia, making it rather 
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i NINCDS-ADRA - National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (now known as the Alzheimer's Association)
impossible to understand this disease without firstly approaching the later 
concept. 
Robert et al. (1994), define Dementia as a clinical syndrome of gradual onset, 
involving loss of intellectual functions and memory, while maintaining normal 
consciousness. 
A more precise definition was given by the WHO (1992), on their tenth revision of 
the ICDi manual, where both Dementia as well as Alzheimer’s Disease, are 
comprised on a block of mental disorders of common etiology, called “Mental and 
Behavioural Disorders”: 
“Dementia is a syndrome due to disease of the brain, usually of a chronic or 
progressive nature, in which there is disturbance of multiple higher cortical 
functions, including memory, thinking, orientation, comprehension, calculation, 
learning capacity, language, and judgement. 
Consciousness is not clouded. The impairments of cognitive functions are 
commonly accompanied, and occasionally preceded, by deterioration in emotional 
control, social behaviour, or motivation. This syndrome occurs in Alzheimer 
disease, in cerebrovascular disease, and in other conditions primarily or 
secondarily affecting the brain.” 
(World Health Organisation 1992)
On the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-V), in order to precisely differentiate the disease, and eventually mitigate 
stigmatization issues, the American Psychiatric Association (2013) takes the 
definition one step further, replacing the term Dementia, previously considered 
an entity of its own, subsuming it under a new subject named Major 
Neurocognitive Disorders (MCD). 
The new entity is now included in a narrower category of a vast group of 
Neurocognitive Disorders (NCD), whose primary clinical deficit is cognitive 
function [Delirium, Major Cognitive Disorder (MCD) and Mild Cognitive Disorder 
(mCD)].
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i ICD-10 - International Classification of Diseases, 10th revision
Consequently, Major Cognitive Disorder and Mild Cognitive Disorder integrate 
Neurocognitive Disorder due to Alzheimer’s Disease and some other various 
subtypes out of the scope of the present paper, namely: vascular NCD; NCD with 
Lewy bodies; NCD due to Parkinson's Disease; frontotemporal NCD; NCD due to 
traumatic brain injury; NCD due to HIV infection; substance/medication-induced 
NCD; NCD due to Huntington's disease; NCD due to prion disease; NCD due to 
another medical condition; NCD due to multiple etiologies; unspecified NCD 
(American Psychiatric Association 2013).
The establishment of the Neurocognitive Disorder is based on the patient’s 
cognitive state, analyzed within delimited and specific cognitive domains:
-Complex Attention (sustained attention, divided attention, selective attention, processing speed);
-Executive Function (planning, decision making, working memory, responding to feedback,/error 
correction, overriding habits/inhibition, mental flexibility);
-Learning and Memory (immediate memory, recent memory [including free recall, cued recall, and 
recognition memory], very-long-term memory [semantic; autobiographical], implicit learning);
-Language (expressive language [including naming, word finding, fluency, grammar, syntax and 
receptive language])
-Perceptual-Motor Abilities (includes abilities subsumed under the terms visual perception, visuo-
constructional perceptual-motor praxis, and gnosis), 
-Social Cognition (recognition of emotions, theory of mind). 
(American Psychiatric Association 2013)
By its turn, differentiation between Major and Mild forms of Neurocognitive 
Disorders occurs both at the level of a cognitive decline from a previous level of 
performance in one or more cognitive domainsi, as well as to the extent that 
those cognitive deficits interfere with normal daily activities of the patientii (table 
2).
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i Major form usually results from significative decline, whereas Mild form is diagnosed when in presence of a modest decline
ii Major form is diagnosed when there is loss of independence whereas is Mild form the cognitive deficits do not interfere with the ability to perform 
everyday tasks independently
Major Cognitive 
Disorder (MCD) is 
diagnosed when the 
following is present:
A. Evidence of significant cognitive decline from a previous level of 
performance in one or more cognitive domains (complex attention, 
executive function, learning and memory, language, perceptual-
motor, or social cognition) based on:
1. Concern of the individual, a knowledgeable informant, or the 
clinician that there has been a significant decline in cognitive 
function; and 
2. A substantial impairment in cognitive performance, 
preferably documented by standardized neuropsychological 
testing or, in its absence, another quantified clinical 
assessment. 
B. The cognitive deficits interfere with independence in everyday 
activities (i.e., at a minimum, requiring assistance with complex 
instrumental activities of daily living such as paying bills or 
managing medications).
C. The cognitive deficits do not occur exclusively in the context of a 
delirium.
D. The cognitive deficits are not better explained by another 
mental disorder (e.g., major depressive disorder, schizophrenia).
Mild Cognitive 
Disorder (mCD) is 
diagnosed when there 
is:
A. Evidence of modest cognitive decline from a previous level of 
performance in one or more cognitive domains (complex attention, 
executive function, learning and memory, language, perceptual 
motor, or social cognition) based on:
1. Concern of the individual, a knowledgeable informant, or the 
clinician that there has been a mild decline in cognitive 
function; and
2. A modest impairment in cognitive performance, preferably 
documented by standardized neuropsychological testing or, in 
its absence, another quantified clinical assessment.
B. The cognitive deficits do not interfere with capacity for 
independence in everyday activities (i.e., complex instrumental 
activities of daily living such as paying bills or managing 
medications are preserved, but greater effort, compensatory 
strategies, or accommodation may be required).
C. The cognitive deficits do not occur exclusively in the context of a 
delirium.
D. The cognitive deficits are not better explained by another 
mental disorder (e.g., major depressive disorder, schizophrenia).
Table 2 - Diagnostic criteria for Major and Mild Neurocognitive Disorder - adapted from (American Psychiatric 
Association - DSM-5 Task Force 2013)
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AD diagnosis is therefore rather complex, and follows four major benchmarks 
(see table 3).
Criterion A states that criteria for MCD or mCD is met
Criterion B states the insidious onset and gradual progression of the 
impairment in one or several cognitive domains (in MCD at least 
two)
Criterion C specifies the difference between PROBABLE and POSSIBLE AD 
etiology
Major Cognitive Disorder:
Probable Alzheimer’s Disease is 
diagnosed if either of the following is 
present, otherwise, Possible 
Alzheimer’s Disease should be 
diagnosed:
-There is evidence of a causative 
Alzheimer’s Disease genetic mutation 
from family or genetic testing,
-All three conditions are met
a)Clear evidence of decline in memory 
and learning in one cognitive domain;
b)Steadily progress with gradual 
decline in condition; 
c)No evidence of mixed aetiology 
(absence of other neurodegenerative 
or cerebrovascular disease, or other 
neurological, mental, or systemic 
disease or condition likely 
contributing to cognitive decline).
mild Cognitive Disorder:
Probable Alzheimer’s Disease is 
diagnosed when in presence of a 
causative AD genetic mutation from 
either genetic testing or family 
history. 
Possible Alzheimer’s Disease 
-There is NO evidence of a causative 
AD genetic mutation from either 
genetic testing or family history, 
-All three conditions are met:
a)Clear evidence of decline in memory 
and learning; 
b)Steadily progressive, gradual decline 
in cognition, without extended 
plateaus; 
c)No evidence of mixed aetiology (i.e., 
absence of other neurodegenerative or 
cerebrovascular disease, or another 
neurological or systemic disease or 
condition likely contributing to 
cognitive decline)
Criterion D states that the NCD must NOT have another etiology beyond 
Alzheimer, this is, the condition must not be better explained by 
cerebrovascular disease, another neurodegenerative disease, the 
effects of a substance or another mental, neurological or 
systemic disorder.
Table 3 - AD diagnose criteria (American Psychiatric Association - DSM-5 Task Force, 2013, p. 611)
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2.1.1
Diagnostic Markers & Biological evidences
On a biological level, structures most affected by Alzheimer’s Disease include the 
brain’s neocortex and hippocampus.
In early onset cases, genetic testing is possible in one of the known causative AD 
genei, but the definitive diagnosis comes from fulfillment of the clinical criteria 
described above, plus evidence of histologic post-mortem analysis (Mayeux and 
Sano 1999); (Perl 2010); (Ballard, Gauthier et al. 2011).
Often times, however, clinicians have to cope with availability and validity issues 
for many of the biomarkers of the disease, making cerebral biopsy the only 
widely accepted method to diagnose definite AD. On these patients’ cerebral 
biopsy, cortical atrophy is observed, as well as B amyloid deposition in senile 
plaques and also intracellular formation of neurofibrilary tangles with abnormal 
phosphorilated form of a microtubule associated proteinii at the level of the 
limbic region and the parietal-temporal cortex with concomitant loss of neuronal 
synapses and pyramidal neurons (Francis, Palmer et al. 1999); (Perl 2010); 
(Ballard, Gauthier et al. 2011); (American Psychiatric Association - DSM-5 Task 
Force 2013).   
In late onset cases, besides the build-up of Beta amyloid protein, de la Torre 
(2004) suggest cerebral hypo-perfusion as a possible mechanism for neuronal 
degenerescence. 
According to the NICEiii clinical guideline 42 on the subject of Dementia, health 
care staff should firstly start by investigate basic hematology as well as 
biochemistry, thyroid function, vitamin B12 serum and folate levels, after what, 
the focus should turn to patients anamnesis, physical examination, evaluation of 
current medication (screening for drugs that might impact on the patients 
cognitive function), and of course, Cognitive and Mental Examination.
Concerning this later recommendation, a set of neurocognitive tests are 
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i (B) beta Amyloid Percursor Protein (APP) gene, on chromosome 21
ii Tau protein
iii National Institute for Health and Clinical Excellence
suggested to be performed on the patient, namely the Mini Mental State 
Examination (MMSE), 6-Item Cognitive Impairment Test (6-CIT), General 
Practitioner Assessment of Cognition (GPCOG) and 7- Minute Screen test, taking 
into account factors like educational level and skills psychiatric illness, physical 
and neurological problems, language and sensory impairment. Also in the case of 
individuals with learning disabilities, alternative tests are proposed, like the 
Cambridge Cognitive Examination (CAMCOG), the Modified Cambridge 
Examination for Mental Disorders of the Elderly (CAMDEX), the Dementia 
Questionnaire for Mentally Retarded Persons (DMR) or the Dementia Scale for 
Down Syndrome (DSDS) (also useful in people without Down's syndrome).
For further definition of the subtype of dementia, NICE guidelines 
recommendations include the NINCDS-ARDA criteria, ICD-10 or DSM-IV, already 
addressed above (National Institute for Health and Care Excellence 2006).
2.1.2
Risk and prognostic factors
Several aspects may be pointed out as possibly increasing the likelihood of 
developing AD, among which: sociodemographic factors; familial and genetic 
factors; cognitive function (as in education and intelligence); medical and 
pharmacological history; and of course, life-style habits (Ames, Burns et al. 2005). 
Among these, family history of dementia, (specially when the disease occurs on 
first degree relatives), head injury and specially age seem to be the strongest 
predictors (Gentleman and Roberts 1992); (Ames, Burns et al. 2005).
Age is, in fact, quoted as the strongest risk factor in Alzheimer’s Disease. This is 
probably one of the main reasons for its common late detection, since it is 
considered normal to somehow loose pristine memory function as one grow old. 
But the fact remains that the process of aging itself is not cause for dementia, nor 
for that matter, AD, because the regular decrease in neurological and 
psychomotor symptoms that normally arouse with the aging process is NOT of 
sufficient severity to cause dysfunction that disturbs daily activities (Robert L. 
Kane, Joseph G. Ouslander et al. 1994); (Petersen, Doody et al. 2001); (American 
Psychiatric Association - DSM-5 Task Force 2013).
To better help general public differentiate Alzheimer evidence signs, from normal 
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aging signs, the Alzheimer’s Association established a list composed of ten 
warning signs for the early detection of the diseasei (refer to table 4).
Alzheimer’s Disease 
warning signs
1-Memory loss that disrupts daily life
2-Challenges in planning or solving problems
3-Difficulty completing familiar tasks
4-Confusion with time or place
5-Trouble understanding visual images and spatial relationships
6-New problems with words in speaking or writing
7-Misplacing things and losing the ability to retrace steps
8-Decreased or poor judgment
9-Withdrawal from work or social activities
10-Changes in mood and personality
Table 4 - Ten warning signs of AD - adapted from (Alzheimer's Association 2012)
2.1.3
Disease Course and Pharmacological Treatment
As the clinical picture evolves, specific signs of functional impairment gradually 
increase. Both cognitive deficits as well as psychobehavioural changes poses 
serious challenges to the patients daily routines, with several dimensions within 
their life being affected. What often started years before, as a subtle amnesic 
episode, may result a few years later in an fully dependent human being, 
oblivious to its surrounding world (ESRO 2014).
General measures as exercise, good nutrition and social interaction are a relative 
imperative for the recovery of many life threatening diseases, and as was to be 
expected, so in here, prevention and prophylactic measures have an important 
role (Ballard, Gauthier et al. 2011).
Besides that, and when defining a therapeutic strategy, one might think of the 
general picture, which in the case of neurocognitive diseases is a rather 
complicated task because of the diversity of symptoms that arise during its 
course - from depression to behavioral problems, an array of symptoms usually 
demands an array of measures. 
Pharmacological treatment in Dementia, Alzheimer’s Disease and cognitive 
impairments therefore, seems limited in the way that there isn’t one substance 
14 |114
i as the original
capable of reverting the complex picture of the disease, which usually includes 
symptoms of agitation, aggression, wandering, depression and apathy (Zec and 
Burkett 2008).
Concerning solely neurocognitive disorders, several classes of medicines are used 
to revert the symptoms of the cognitive deficit, namely: nootropics, (stimulant 
medicines as piracetan); cerebral vasodilators (ergot, papaverin isoxsuprine); 
calcium channel blockers as nimodipine; N-methyl-D-aspartate receptor 
antagonists (Memantine) and cholinesterase inhibitors (Goodman 1996); (Sink, 
Holden et al. 2005); (Birks 2006); (National Institute for Health and Care 
Excellence 2006); (National Institute for Health and Clinical Excellence 2011).
From these pharmacological classes, one stands out when it comes to 
Alzheimer’s Disease. Aimed specifically at coping with the cognitive symptoms 
experienced by AD patients, acetylcholinesterase inhibitors (AChEi) are amongst 
the most widely used drugs in clinical practice, acting by limiting the breakdown 
of acetylcholine in synaptic clefts, thus increasing cholinergic synaptic 
transmission, and hence, its concentration on the brain - examples include 
Donepezil, Rivastigmine, Galantamine (Francis, Palmer et al. 1999); (Birks 2006) 
(Lanctot, Herrmann et al. 2003); (Trinh, Hoblyn et al. 2003);  (National Institute 
for Health and Care Excellence 2006, National Institute for Health and Clinical 
Excellence 2011).
Choline acetyltransferase and acetylcholinesterase are both found in high 
concentration on cholinergic neurons and cholinergic brain synapses. 
These enzymes are responsible for the synthesis and respectively the degradation 
of acetylcholine (ACh), a neurotransmitter with a major indirect influence on 
memory and on the learning process (Perry, Tomlinson et al. 1978); (Francis, 
Palmer et al. 1999); (Kaduszkiewicz, Zimmermann et al. 2005).
These medicines act on the basis of neurodegeneration of the basal forebrain, as 
the reduction of acetylcholine and/or choline acetyltransferase (ChAT), imposes 
serious impairments on patients memory (Perry, Tomlinson et al. 1978); (Francis, 
Palmer et al. 1999); (Mayeux and Sano 1999).
“since 2006, literature on new agents for the pharmacological management of AD 
and other dementias has been characterized by disappointing failures” 
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(Herrmann, Lanctot et al. 2013)
Increasing cholinergic neurotransmission is therefore a way to revert the 
cognitive deficit experienced by AD patients, justifying the recent focus of the 
pharmaceutical industry on the development of this class of drugs. Even so, 
although pharmacological treatment with AChEIs shows some improvement in 
neuropsychiatric and functional level of clinical significance, Trinh et al. (2003) 
consider this benefits to be of modest magnitude in mild to moderate 
Alzheimer’s Disease , furthermore, despite this moderate beneficial effect, 
discontinuing AChEIs may lead to worsening of symptoms, a situation in which 
the clinician has to balance the option to continue pharmacological treatment 
versus the risk of the therapy side effects (Kaduszkiewicz, Zimmermann et al. 
2005); (Sink, Holden et al. 2005).
2.2
SCALES AND ASSESSMENT
Effective clinical diagnose of Alzheimer’s Disease, requires the usage of 
neuropsychological tests to measure cognitive, behavioural and functional 
assessments, according to a prevailing diagnostic criteriai. 
As the disease progresses, the symptoms are gradually manifested with ever 
higher intensity and developing a suitable instrument capable of differentiating 
between several types of dementia as well as categorizing the stage within that 
particular type is a challenging endeavor. 
Besides the specificities of validation, reliability and sensitivity criterium, the 
subjects under evaluation tend to be elderly, with a rather complicated 
symptomatological picture, which in all, confers upon them characteristics of 
short cooperation periods, making it hard to develop and administer such a 
measuring tool. Robert et al. (2010) summarized the ideal characteristics of a 
multi-domain AD scale for daily medical practice:
1) Easy and quick administration by an experienced clinician; about 10 minutes administration time
2) Reliable and valid for AD
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i NINCDS-ARDA, DSM-IV, ICD-10
3) Covering AD relevant areas, like cognition; activities of daily living; behaviour; communication 
and social interaction and quality of life 
4) Applicable to all AD severity stages (with minimal floor and ceiling effects)
5) Useful for monitoring disease progression in clinical practice
6) Sensitive to measure therapy effects
adapted from (Robert, Ferris et al. 2010)
Assessment tools used to evaluate the outcome of a given therapeutical measure 
in the case of Probable or Possible Alzheimer’s Disease, include an array of 
cognitive and functional tests with two of the most commonly used being the 
Mini Mental State Examination (MMSE) and the Alzheimer’s Disease Assessment 
Scale - cognitive sub-scale (ADAS-cog) (Folstein, Folstein et al. 1975); (Birks 2006); 
(National Institute for Health and Care Excellence 2006); (National Institute for 
Health and Clinical Excellence 2011); (Robert, Ferris et al. 2010); (Bossers, van 
der Woude et al. 2012).
In a recent literature review of 89 RCTis, with the objective to recommend a group 
of neuropsychological tests to use in clinical trials for cognition assessment in 
older patients with dementia, Bossers et al. (2012) refer the Severe Impairment 
Battery (SIB), Mini Mental State Examination (MMSE) and Alzheimer Disease 
Assessment Scale (ADAS-cog) as tests commonly used to evaluate global 
cognition. 
From these later, MMSE and ADAS-cog where the most often administered for this 
purpose, with the majority of interventions (84%) being made on Alzheimer’s 
Disease diagnosed patients, independently of the type of intervention 
(pharmacological, acupuncture, exercise, etc.). 
In terms of reliability, these same authors conclude that MMSE is both reliable 
and valid in dementia patients, although with a floor effect in severe dementia 
(Bossers, van der Woude et al. 2012).
2.2.1
Tests Description
MMSE - Mini Mental State Evaluation
The Mini Mental State Evaluation test is a simplified and scored form of cognitive 
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i Randomized Control Trial(s)
mental status evaluation, analyzing cognition in seven different categories, 
namely:  Orientation; Immediate Recall (Registration); Attention, Calculation; 
Delayed Recall, Language and Visual Construction. 
It encompasses a 30 point scale, comprising eleven questions aimed specifically 
at the evaluation of the severity of the cognitive impairment. Although there is 
not a specific time limit to its completion, it usually doesn’t take more than 5-10 
minutes to administer.
The test is divided into two sections - the first part requires only vocal answers 
and covers orientation, memory and attention, while a second part tests the 
ability to name, follow verbal and written commands, spontaneously write a 
sentence and copy a geometrical form (Folstein, Folstein et al. 1975); (Chaves ML 
2011); (Bossers, van der Woude et al. 2012).
Folstein (1975) proved its validity and reliability as an initial and serial measuring 
tool, allowing the follow up of cognitive function over time, with or without 
treatment. However, Bowie et al. (1999), when assessing MMSE reliability on 
detecting small changes in cognitive function, has drawn a different conclusion, 
stating that the test is not powerful enough to detect score differences, when 
changes in cognitive function are small, allegation which is also supported by the 
Wessex Institute for Health Research and Development on the its paper on the 
Clinical and Cost Effectiveness of Donepezil, Rivastigmine and Galantamine for 
Alzheimer’s Disease  (Clegg, Bryant et al. 2002).
The 30 point MMSE scale allows the differentiation of the degree of severity of the 
disease, where an increase in numeric value represents an improvement in 
cognitive function (table 5).
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Mini Mental State Examination
Item Description and valuation Score
Orientation (10 points)
Immediate Recall (Registration) (3 points)
Attention and Calculation (5 points)
Delayed Recall (3 points)
Language (3 points)
Visual Construction (3 points)
Follow Instructions (3 points)
Mild AD: MMSE 21 to 26
Moderate AD: MMSE 10 to 20
Moderately severe AD: MMSE 10 to 14
Severe AD: MMSE less than 10.
Table 5 - Mini Mental State Examination description and score
In the scope of the present article, we will use the MMSE (Mini Mental State Exam) 
as a cognitive screening instrument. The reasons behind this choice are the 
relative easy of usage, its broadly acceptance as an instrument for the measure of 
cognitive loss (Chaves ML 2011); (Bossers, van der Woude et al. 2012).
Alzheimer’s Disease Assessment Scale (ADAS)
Alzheimer’s Disease Assessment Scale (ADAS) was developed by Rosen et al. 
(1984), in order to evaluate the severity of both cognitive and non cognitive 
dysfunctions of individuals with AD. Birks (2006) and Robert (2010) mention the 
fact that this is actually the preferred clinical trials cognitive test, when assessing 
therapeutical efficacy in cognition within AD patients.  
The global scale encompasses 40 items, 11 of them belonging to the assessment 
of cognitive function. 
This 11 items psychometric scale (see to table 6), tests memory, orientation, 
language, attention, reasoning and following instructions abilities (Peña-Casanova 
1997).
Point evaluation range from 0 - No Impairment, to 70 - Very Severe Impairment, 
where a decrease in the score means improvement in cognitive state. The test 
usually takes about 30 to 45 minutes to administer and it seems to be specially 
suited for patients suffering from moderate stage of the disease.
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Alzheimer’s Disease Assessment Scale - cognitive subscale
Items description and 
point valuation
Spoken Language Ability (0-5)
Comprehension of Spoken Language (0-5)
Recall of Test Instructions (0-5)
Word Finding Difficulty (0-5)
Following Commands (0-5)
Naming Object (0-5)
Construction Drawing (0- 5)
Ideational Praxis (0-5)
Orientation (0-8)
Word Recall (0-10)
Word Recognition (0-12)
Table 6 - ADAS-cog, cognitive domain valuation
The challenges posed by both MMSE and ADAS-cog, are usually related to their 
lack of sensitivity on early stages of the disease, and specifically when it comes to 
ADAS-cog, the fact that it does not include items for dictation, abstraction, 
calculation and problem solving (Peña-Casanova 1997); (Robert, Ferris et al. 
2010).
Clock Drawing Test
Despite not being a definite indicator of AD and more suited to access executive 
functioning, the Clock Drawing Test aids researchers and clinicians assess the 
degree of dementia severity (Bossers, van der Woude et al. 2012).
The test involves complex and simultaneous cognitive, motor and perceptual 
abilities for successful completion. Different investigators use divergent forms of 
administration, most of them involving asking the patients to draw the face of a 
clock in a piece of paper. The patient is later asked to fill in the numbers and the 
arms of the clock, so that they represent “ten minutes after eleven” (Shulman 
2000); (Fuzikawa, Uchôa et al. 2003).
Various methods of scoring are described in literature, and overall best scores 
result from correctly drawing and spacing the numbers as well as placing the 
clock hands at the asked time (Brodaty and Moore 1997). Shulman (2000) 
proposed a simple method for scoring - classifying errors from 1 to 5 -, where 
better performances are positively correlated with higher punctuations.  
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The advantages of using the clock drawing test remain the simplicity of its 
administration, its low cost, the fact that it doesn’t need any specific materials, as 
well as its high levels of sensitivity and specificity as a cognitive screening 
instrument. When used in combination with MMSE, the combined sensitivity and 
specificity of both tests for differentiating between patients with AD, Mild 
Cognitive Impairment and Healthy Controls is superior to MMSE, when it is used 
alone, and similar to ADAS-cog, with the benefits of an easier and faster 
administration (Shulman 2000); (Fuzikawa, Uchôa et al. 2003); (Kato, Narumoto et 
al. 2013).   
Dementia Rating Scale
Another practical prominent scale for usage on the evaluation of cognitive 
capacity of subjects with neurological impairments is the Dementia Rating Scale 
(DRS) (Jurico, Leitten et al. 2011).
The DRS i is both useful in the early diagnose of dementia as also in stage 
classification. It encompasses 36 chores and 32 stimuli, organized on the course 
of five sub scales, allowing the collection of information on specific cognitive 
abilities namely: Attention; Initiation/Perseverance; Construction; 
Conceptualization; Memory.
One of the advantage of this scale is the progressive (or hierarchic) rating system, 
according to which more difficult tasks are presented at first within each sub 
scale, meaning that on successful completion of any of these first tasks, the 
surveyed subject gets credit for tasks to come that belong to the same group, 
allowing them to move forward to the following group of tasks. 
This procedure, in all, allows reduction of the test completion time to 10 to 15 
minutes in patients with normal cognitive function, (the test takes approximately 
30 to 45 minutes to administer in moderately impaired subjects). 
Another asset in favor of this scale in the scope of the present study, is the fact 
that it is currently validated for usage in the portuguese population and also the 
strong evidence of the test’s reliability and internal consistency on AD patients 
(Vitaliano, Breen et al. 1984); (Matteau, Dupré et al. 2011).
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i Dementia Rating Scale
2.2.2
Pharmacological Treatment and Neuropsychological 
Scales
On a systematic review of randomized clinical trials, 22 publications from a total 
of 412 references met the inclusion criteria for the evaluation of possible 
scientific evidence of the clinical benefits of AChEIsi (Donepezil, Galantamine and 
Rivastigmine) in AD patients. Of these trials, 14 publications used ADAS-cogii as 
the psychometric test to measure the outcome in terms of cognitive function, 
from which 12 yielded significative differences when comparing the usage of 
AChEIs with placebo. 
In terms of the improvement on the measuring tool (ADAS-cog), mean differences 
ranged from 1,5 points to 3,9 points (Kaduszkiewicz, Zimmermann et al. 2005).
Birks et al. (2009), reviewed the effects of Rivastigmine on AD, analyzing 9 
unconfounded, double-blinded, randomized studies, where the drug was 
administered to a total of 4775 AD diagnosed patients for more than two weeks, 
with initial MMSEiii scores from 10 to 26. 
Results of cognitive function showed improvements for Rivastigmine dosages 
between 6 to 12mg daily, where MMSE increased by 0,8 points and ADAS-Cog 
decreased by 2,1 points. On groups receiving 1 to 4mg daily, improvements were 
also felt, although they where not as strong, as those obtained with higher 
dosages. 
These results are inline with those obtained earlier by Rosler, et al. (1999), where 
patients receiving the same Rivastigmine dosage (6 to 12mg/daily), over a 26 
week period, improved on ADAS cognitive sub-scale  by a mean of 1,2 point 
score. 
Another review by Birks (2006) included a total of 7298 patients distributed 
through 13 trials, all multi-centered, randomized, double-blinded and parallel. 
Patients were diagnosed with Mild AD in 1 trial (mean MMSE 24); Mild to Moderate 
AD in 10 trials (MMSE 17 to 20); and Severe AD in 2 trials (MMSE 12 and 14 
respectively). 
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i Acetyl Cholinesterase Inhibitor
ii Alzheimer’s Disease Assessment Scale - cognitive sub-scale
iii Mini Mental State Examination
From the total number of patients, 2228 received Donepezil, 2267 Galantamine 
and 2803 Rivastigmine. 
The patients were screened for Global assessment, Cognitive Function, Activities 
of Daily Living and Behavioural Disturbance, yielding the following results 
concerning Cognitive Function after approximately 6 months treatment: 
-10 studies contributed to ADAS-cog meta-analysis (3 concerning treatment with 
Donepezil, other 3 with Galantamine, and the remaining 4 with Rivastigmine). The 
treatment effect revealed a decrease from 1,4 and 3,9 points on ADAS-cog scale, 
from which Rivastigmine showed more variation both in treatment as in placebo 
group, effect not felt with the any of the other medicines.
-9 studies contributed to MMSE meta-analysis (5 concerning treatment with 
Donepezil and 4 Rivastigmine), with treatment effect ranging between 0,65 and 
1,8 points in eight of the trials. 
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3TRADITIONAL CHINESE 
MEDICINE
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3.1
BACKGROUND
The World Health Organization (2010) recognizes Traditional Chinese Medicine 
(TCM) as a variety of therapies and medicinal practices employed in China for the 
last two millennia, developed from clinical experience and recorded in classical 
ancient scripts. The first known book on the subject of Chinese Medicine, the 
Huangdi Neijing - the Yellow Emperor Cannon of Internal Medicine -, dates back to 
the years 475–22BC and documents human structure and physiology as well as 
disease pathophysiology and treatment procedures.
Nowadays, higher education on TCM is available, not restricted to universities and 
colleges throughout China, but also in several other developed countries (World 
Health Organization 2010). More than ever, it is crucial to establish the bridge 
between both knowledges, a kind of “West meet East”, allowing the incorporation 
to each of these medicine concepts, the best both have to offer.
Chinese medicine concepts stand on the basis of Confucianism, Daoism and 
Taoist philosophy to explain its holistic medical reasoning concept, according to 
which the human being and its surrounding environment are in constant 
equilibrium. Understanding the “laws” of nature is therefore paramount to 
interpret how living organisms respond and reflect the macrocosmos (or the 
environment). Within this equation, metabolism, homeostasis and adaptation are 
the basis for life, and this point of view of the human body as an open system, 
considers all of its structures and components as interrelated subsystems 
establishing functional relations, so that a rather complex dynamic balance must 
be obtained to achieve a disease free organism.
Due to political and cultural restrains, both inbound and outbound information in 
and from ancient China was scarce, resulting in part of this knowledge being lost 
throughout time, as well as rather difficult to interpret in light of an western 
educated mind. Naturally, with all the advances observed in the last centuries in 
the fields of medicine, physiology, pathophysiology and anatomy, western 
medicine concept grew apart this ancient oriental knowledge. Nevertheless, along 
with the continuous development of Tradicional Chinese Medicine, several 
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schools and scholars have been making an effort to recover information and 
systematize it, seeking a modern and more rational interpretation of specific 
intricate TCM concepts, to find its equivalency and usefulness to Western 
Medicine (Porkert, Hempen et al. 1999); (Teppone and Avakyan 2009); (Greten 
2011, Greten 2012); (Tsui 2013).
An enlarged understanding of TCM is out of the scope of the present study, 
however, several theories on the basis of Tradicional Chinese Medicine will be 
addressed, namely the Theory of Yin and Yang, Theory of the Five Movements 
(Phases), the Theory of Qi and the Conduit System. 
3.1.1
TCM Definition
According to the Heidelberg School of Chinese Medicine (Greten 2011), 
Traditional Chinese Medicine is a system of findings and sensations, designed to 
evaluate the functional vegetative state of the body, further treated by an array of 
tools such as Chinese Dietetics, Psychosomatic TCM, TuiNa Massage, Chinese 
Phytopharmacology, QiGong and of course the most known of all the techniques 
within TCM, Acupuncture. 
Porkert et al. (1999), defines health in the scope of Chinese Medicine, as the 
capacity to maintain orthopathyi - “the tendency or the capacity of an individual to 
maintain integrity (…) well-balanced physiological, intellectual, emotional 
functions”. 
This later state is, however, challenged by several factors, impacting the system 
as a hole, or in respect to its particular features. In a sense, in the scope of TCM’s 
theory, restoring one’s health translates to restoration or normalization of these 
imbalances (Teppone and Avakyan 2009).
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i Within the scope of the scientific vegetative Heidelberg Model of Chinese Medicine, a hole new hermeneutic system was developed in order to 
translate TCM concepts in light of medical western thinking. Orthopathy symbolizes literally “straight running functions”
3.1.2
Theory of Yin and Yang
“All things connote the Yin and yang. The Yin and Yang keep acting upon each 
other. And thus things keep changing and unifying themselves” 
(Roberts 2004)
Yin and Yang are probably amongst the most world widely spread concepts of 
Chinese culture. They relate to each other like both sides of one same coin - it is 
not possible to explain one without the other.
Chonghuo (1993) postulates the following, regarding Yin and Yang concepts:
Postulate 1
Yin and Yang Contradiction
Every phenomenon of nature, has, at the same time, two opposites; 
Postulate 2
Yin and Yang are Complementary
Each of the opposites exists as long as there is the other. There is no Yin without Yang, and vice-
versa. When one them is not present, there is no possibility for life to exist; 
Postulate 3
Growth and Decline Relation of Yin and Yang
Change and movement is the essence of both Yin and Yang. If one grows, the other retracts in order 
to obtain a dynamic equilibrium. An example are the changes seen in environmental seasons - from 
Spring to Summer, Yang heat increases, while Yin cold decreases. Also in living organisms, general 
physiologic function (Yang) increases through consumption of nutrition (Yin). This balance is always 
compensated to the point that If one of them rises or decreases too rapidly the balance is broken 
and disease might arise; 
Postulate 4
Yin and Yang transmutation
By which Yin becomes Yang and Yang becomes Yin.
There is not one, but several approximate metaphorical meanings for these 
concepts. In the spectrum of both Chinese Medicine and Chinese Culture, the 
terms are applied to describe functional relations:
-Where the Yang is pictorially represented by the sunnier side of a mountain, the Yin will be 
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illustrated by the shadier side of that same mountain;
-The Yang represents a state of higher energy when compared to its counterpart the Yin, with lesser 
energy; 
-When the Yang represents expansion the Yin will be contraction; 
-The Yang, relates to anything in the state of “more on the outside” compared to the Yin, “more on 
the inside”;
-The Yang finds parallelism with the function, but that function arises from the Yin, represented by 
the structure;
-The Yang is a state of more disperse energy, and the Yin a state where that same energy is more 
dense;
-The Yin is represented by Winter whereas the Yang is the Summer, or the Yang might be Spring, 
compared to Autumn that is Yin;
-...and so forth...
In the same way that the relation is found in nature and all things, likewise every 
body part and structures exhibit Yin and Yang aspects. The anterior part of the 
body is Yin in relation to the posterior that is Yang, the upper part is Yang in 
relation to the lower part which is considered Yin. Organs also fall into this type 
of categorization - for this matter, TCM established organ pairs that are 
functionally related in both cyclic and in a counter-regulatory way. 
Another manner to describe this terms is by the usage of numbers. The Chinese 
Monad is the perfect example of this statement. Together, Yin and Yang describe 
a relationship between apparent opposite sets that counterbalance each other, 
and translating them into a binary mathematical comparison system, every aspect 
of life can be described using different combinations (Porkert, Hempen et al. 
1999); (Teppone and Avakyan 2009).
The understanding of the Yin and Yang theory is therefore fundamental to the 
understanding of Tradicional Chinese Medicine itself. Restoring health in the view 
of TCM, relies on the equilibrium of these counterparts (Cheung 2011); (Tsui 
2013); (Zhang and Wang 2014).
3.1.3
The Theory of the Five Movements (Phases)
The basis of TCM, holds that there is a parallelism between nature and living 
organisms, stating that they exhibit similar rhythmical changes and functioning. 
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As the environment is cyclically divided in four seasons, the same relation can be 
seen in living organisms. TCM considers four basic movements, often known as 
elements: Wood (related to Spring); Fire (related to Summer); Metal (related to 
Autumn); Water (related to Winter) and a special fifth with very specific functions 
- the Earth.
According to Tsui, (2013) this model of the five movements is explainable in light 
of sequential functional restrains and promotions suffered by each movement in 
the continuum.
The vegetative Heidelberg Model of Chinese Medicine relies on a simplified 
concept of cybernetic regulation, where vegetative functions are continuously 
being expressed in a circular style, resulting in a likewise sinus curve (figure 1) 
(Greten 2011). 
Figure 1 - Sinus wave as basis for theoretical approach to the Heidelberg Model of Chinese Medicine
On this mathematical/vectorial pictogram, all of the body’s regulatory function 
are expressed as a relation to a baseline value representing the homeostasis 
threshold (the horizontal line).
The part of the graphic above the threshold represents several Yang aspects of 
regulation and the lower part, Yin aspects of regulation. Each quarter of a cycle 
represents a phase and at each inversion point, a new phase arises from the later.
With this model, Greten (2011, 2012) circumvents the misleading use of the term 
element, defining instead the phase - a cybernetic or regulatory term, part of a 
circular process, symbolizing a functional vegetative tendency which is 
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manifested in a specific body part by means of clinically relevant signs and 
symptoms named orbsi. 
Like Spring turns into Summer, which in turn gives place to Autumn and this later 
to Winter, this natural movement of seasons is illustrated by this regulatory 
model, where the phase Wood transitions to the phase Fire, this one into Metal 
and the later into Water. To this, the phase Earth is added, representing the dow-
regulation or up-regulating vector that powers the phase transitions, resulting in 
a total of eight phase transitions (Wood-Earth-Fire-Earth-Metal-Earth-Water-Earth-
Wood).
Furthermore, each phase encompasses two organs or Orbs (exception made to 
the phase Fire which was later on split in four orbs for scientific systematization 
reasons), each of them presenting either a Yin or Yang predominant aspect (table 
7).
Phase Yin orb
Associated 
Yin Organ Yang orb
Associated 
Yang Organ
Wood Hepatic Orb  Liver Felleal Orb Gall Bladder
Fire Cardial Orb Heart Tenueintestinal 
Orb
Small Intestine
Fire (2) Pericardiac Orb x Tricaloric Orb x
Earth Lienal Orb Spleen & Pancreas Stomachal Orb Stomach
Metal Pulmunal Orb Lung Crassintestinal Orb Large Intestine
Water Renal Orb Kidney Vesical Orb Bladder
Table 7 - Yin and Yang Orbs according to the respective phase
According to Gretens’s (2012) model of vegetative regulation, during the Yang 
phases (Wood and Fire), sympathetic nervous system prevails while on Yin 
phases (Metal and Water), parasympathetic stimuli is more expressed. Phases 
Wood and Fire are characterized a hyper-tone and hyper-dynamic vegetative 
state, when compared to Metal and Water, that are respectively more hypotonic 
and hypo-dynamic (figure 2).
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i This term is part of the Heidelberg Model hermeneutics. Although its definition might exhibit some similarities with an actual organ in western 
medicine, an orb is comparable to an organ pattern, or to the signs manifested by that organ
Figure 2 - Sympathetic and Parasympathetic states of the HMCH (Greten 2011)
Consequently, each of the phases presents different specificities within this 
vegetative regulatory system of the living organism. The phase Wood is related to 
the creation of potential. It is associated with ascending movements like the 
increase of excitation, and it is followed by the phase Fire, where the function 
reaches its peak and initiates its down-regulatory movement. Greten describes 
Fire as the phase where transformation of potential into function occurs. The 
following phase, Metal, is described as functional relaxation. With its prevailing 
Yin aspects, there is a relative lack of energy, and by action of the orbs Pulmunar 
and Crassintestinal the energy “descends” and is distributed throughout the body. 
Finally, the phase Water is the regenerative phase of the cycle. Within this phase, 
all functions reach their lower in terms of energy, and initiate their ascend. This is 
why the Renal Orb is considered to be the storage house of the essence, the 
source of energy. 
The phase Earth represents the equilibrium and the power of regulation. The 
movement of the phases is possible because of the Earth’s capacity to up or down 
regulate. This is to say, for instance, that when the maximum Yang is reached in 
Wood, the descending vector Earth, represented by the Stomachal Orb,Xue 
inverts the curve, giving birth to the phase Fire, and on the maximum of Yin in 
Metal, the ascending vector of the Earth phase, the Lienal Orb, brings the energy 
up, “keeping the wheel turning” (Greten 2011).
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3.1.4
Theory of Qi and the Conduit System
Porket et al. (1999) defines Qi as an immaterial energy with a qualification and a 
direction, whereas an auxiliary vegetative definition is brought by Greten (2012), 
stating that Qi represents the “vegetative capacity of an organ or tissue to 
function, which may cause a sensation of tearing, pressure or flow”.
Special qualifications of Qi point to its diverse functions within the system of 
TCM. Original Qi (or Yuan Qi), is the source of all energy, represents the essence 
stored in the Renal orb, the basis of all Yin and Yang energies of the body and it 
is dispersed by the Tricaloric Orb, propelling the organs functional activity and 
assisting the production of Xuei. Another example is defensive Qi, (or Wei Qi) - a 
particular form of Qi located outside the conduit network, believed to ward off 
exogenous pathogens.
Teppone & Avakyan (2009) compare Qi to an universal qualitative measuring unit, 
something that physicians could measure, regulate and manipulate in order to 
achieve different states (which makes sense, since despite that there is no 5Qi ou 
6Qi, TCM tends to qualify divergent states as having more Qi or less Qi). From 
this later statement, inference can also be made in order of the condition of 
excess or deficiency, reflecting respectively, status of high or low activity. 
According to TCM theory, this energy flows within the body through specific 
pathways called “conduits”. Greten (2012) further defines conduitii as a 
“connection of a group of points with effect on the clinical signs of an orb, 
believed to serve as a conduit for the flow of Qi and Xue”. 
The conduit system consists of different pathways, where several connections 
exist between specific body regions, namely intracellular spaces or cavities, by 
which, due to their biological, morphological and functional complexity, 
interactions to the exterior environment occur (Tsui 2013), which is actually the 
basis for acupuncture. In a general sense, imbalances on this flow of Qi might 
result in diverse pathological outcomes and acupuncture is therefore used as a 
means to correct them by choosing specific acupoints within these conduits, that 
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i Within the HMCM, Xue refers to the functional capacity bounded to body fluids, with functions to nurture, moisten, bring warmth and Qi to the 
tissues. It is directly related to effects of microcirculation, which in western medicine is similar concept to the blood.
ii Within International nomenclature, the meridian
in turn will develop specific regulatory actions. 
Tsui (2013) states that the sheer nature of Qi is also important when it comes to 
differentiate the concepts of health and disease. The key aspect here, is once 
again equilibrium. Resorting to an example, heat and cold within the body 
describe intensity of heat production and therefore also the state of Qi. When 
exothermic reactions exceeds the normality threshold, TCM doctors may think of 
a manifesting disease with heat symptoms requiring “cleaning the heat”. The 
opposite is also plausible - when presented with an exacerbated endothermic 
reaction, the physician may be lead to consider an affection by cold, or a cold 
disease, requiring warming therapy.
On a disease free organism, thus, the Qi has both the correct direction and it is 
strong in nature, thus allowing Xue and body fluidsi to effectively nourish the 
tissuesii. When a patient exhibits a healthy Qi, functions are exerted by the 
organs without distress, and there is strong resistance to exogenous pathogenic 
agents.
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i In classical TCM theory, the body fluids have the designation of Jinye
ii We will not approach at this instance the relation between Qi and Xue. It is sufficient for now the understanding that if Qi is healthy, this will 
contribute decisively to the production of “healthy” Xue
3.2
TCM DIAGNOSE
As in Western Medicine, TCM diagnose relies on the gathering of clinical 
information from inspection, palpation, auscultation, olfaction and inquiring. 
Together, all this information is then compiled to attain the Zheng concept, a 
fundamental notion in Chinese Medicine reflecting an organized pattern of all 
clinical manifestations, allowing the differentiation of specific targeted medical 
approaches. In western terminology, one might compare it to the classification of 
a syndrome (Su, Lu et al. 2012).
Concerning the diagnosis, there are four main mechanisms leading to 
imbalances, as principles of disease (Greten 2012):
Excess of an agent i  - the pathogenic factor eliciting the imbalance;
Problems of transition - functional vegetative regulation occurs in a cyclic way 
and a phase expresses a part of this cycle - when transition does not occur, signs 
and symptoms of dysregulation are elicited and the disease is manifested;
Imbalance of antagonizing phases - as the phases are upward and downward 
“vectors” within this model of vegetative regulation, they counterbalance each 
other - when this balance is not present, there is dysregulation, and hence, 
disease;
Yin deficiency - if there is a Yin deficiency, this means that there is a structural 
problem. In western terms, there is not enough cell apparatus to surpass the 
disease.
Greten (2012) systematized the process of diagnosis into four hierarchical 
important stages explained bellow: Constitution, Agent, Orb and Guiding Criteria 
(figure 3).
The first of these steps corresponds to the evaluation of the CONSTITUTION, 
which put simply, is the tendency to predominantly express a specific set of 
signs, revealed in the individual phenotype. The analysis of the constitution leads 
the TCM doctor to generate initial assumptions about the response of the patient 
subjected to different conditions. 
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i An agent is any entity capable of eliciting a disease
Resorting to an example, the therapist usually accounts for telltale signs, 
evidences like the clenching of the fist, the tone of the voice, the expressivity of 
the eyes or the movement of the limbs. These observations are partly common 
sense, but for instance, if the patient’s voice is low, like weeping, and he or she 
present hanging shoulders, this may lead to the assumption of a relative lack of 
energy and feeble constitution.
Figure 3 - Functional Diagnose according to the HMCM (Greten 2012)
The second part of the diagnosis is the definition of the AGENT, which translates 
to the pathological vector eliciting the imbalance, on the etiological origin of the 
disease. 
Agents are categorized as External, Internal and Neutral: 
External Agents find parallelism with environmental conditions experienced by 
the patient:
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Algori - symbolizing the effects on the body resulting from being exposed to cold; 
Calor - symbolizing the effects on the body resulting from being exposed to heat; 
Humor - symbolizing the effects on the body resulting from being exposed to a damp (humid) 
environment;
Ariditas - symbolizing the effects on the body resulting from being exposed to a dry 
environment;
Ventus - symbolizing the effects on the body resulting from being exposed to a draught of air.
Internal Agents, generally refer to exacerbated emotions
Ira - or the over expression of anger;
Voluptas - or the expression of uncontrollable over excitement;
Cogitatio - or the feeling of over thinking;
Maeror - or the feeling of grief and sadness;
Timor - expressing frightfulness.
Neutral Agents refer to substances like toxics, harmful medicines, virus or 
bacteria.
In order to further exemplify the concept of Agent, when referring to cold disease 
or cold attack, TCM clinicians are in fact symbolizing the resulting effects in 
terms of the body physiology, particularly when it comes to microcirculation. 
Being exposed to Algor (or environmental cold), will develop a physiological 
reaction that in time reduces the Xue content over the body surface. This 
diminished microcirculation is later on responsible for a specific set of clinically 
significant signs identified by the physician, called an orb.
The third part of the diagnosis compels the identification of the affected ORB or 
orbs - the observation of clinical relevant signs and symptoms exhibited by a 
certain body region, representing the manifestation of a phase.
Finally, the last part of the diagnose is composed of another four distinctive 
decisions or four GUIDING CRITERIA, that should be interpreted in order to 
understand the underlying mechanisms of the disease. These encompass neuro 
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i The magnitude of the importance of the agent Algor led to the development of a diagnostic system of its own called the “Shang Han Lun”, or within 
the HMTCM “The Algor Ladens Theory” reflected on the book “The Treatise on Cold Diseases and Miscellaneous Disorders” (Shang Han Za Bing Lun) 
dated back to 196–204AD (World Health Organization 2010).
According to the model developed 1.800 years ago, there are “layers” of defense within the body physiology, six to be precise, by which hierarchically 
the agent cold attacks the body. 
A fair pictographic representation might be imagined - six stages (or layers of defense) protect critical organs in the living organisms. Within each 
stage different qualifications of Qi and Xue are responsible for protecting the organs - Algor, the external agent fights each of these organ pairs, until 
it reaches the next, more interior, critical organs.
The three first layers are located on the extima, meaning that orbs affected at these levels are closer to the surface of the body (or more yang), and 
symptoms exhibited will have reflections at these “more superficial” levels (Vesical-Tenueintestinal, Stomachal-Crassintestinal and Felleal-Tricaloric). 
Within these first three stages one might think of more acute diseases. However, the three last stages deal with Yin organ pairs (Pulmunary-Lienal, 
Hepatic-Pericardium, Renal-Cardiac), and affections here, usually have a more profound impact, compared to chronic diseases in western medicine 
(Teppone and Avakyan 2009); (Greten 2012).
and humuro-vegetative signs observed during the course of the disease, namely: 
Repletio/Depletio; Calor/Algor; Extima/Intima; Yang/Yin (table 8).
Guiding 
Criteria
Type Signs
Repletio/
Depletio
Neurovegetative Signs indicating towards a state of more energy or less energy, 
or more Qi or less Qi, or excess, or deficiency
Calor/
Algor
Humoro-
vegetative
Reflect a set of signs related to blood perfusion. 
If there is an increase in microcirculation, the patient experiences 
calor (hot) signs, like thirst, yellowish sparse and concentrated 
urine, red face completion, among others, as a result of the 
increase of microcirculation. 
If however, there is a regional lack of microcirculation the 
patient experiences signs of algor (cold), like pale skin, increased 
sensitivity to cold, etc.. 
Extima/
Intima
Neuro-
imunological
Point to the localization of the affected orb. 
Extimal diseases, therefore, affect mainly the outer orbs, eliciting 
outer organ patterns, likewise inner orbs may also be affected by  
the agent or the imbalance - in which case the manifestation is 
called an Intimal disease. 
The presupposition is that outer orbs are more accessible by 
agents and imbalances, as they are more external, and hence, 
more vulnerable than inner orbs, and when an pathological 
imbalance occurs, manifesting signs will generally occur firstly 
on outer orbs.
Yin/Yang Structural vs 
Regulatory
Wether it is of functional nature - like an exacerbation of a 
regulatory function - in which case it is considered a Yang 
disease, or if the disease affects the structural tissue - Yin 
diseases.
Table 8 - The Guiding Criteria according to the HMTCM
Restoring orthopathy, once again, means reestablishing the normal functioning 
of these vegetative capacities, correcting imbalances in order to maintain 
homeostasis.
In Alzheimer’s Disease, the understanding of which features of the system are 
impaired, is the basis for the development of an assertive therapeutic strategy.
37 |114
3.3
ACUPUNCTURE
The first mention to acupuncture and moxibustion in a medical text appeared on 
the “Inner Classic of the Yellow Emperor” (Huangdi Neijing), dated of 200BC. On 
this historical ancient script, the course of the major conduits was already 
detailed, as well as attributed names and description of sensitive points located 
within these pathways (Porkert, Hempen et al. 1999).
Western civilizations however, took time to embrace the technique. Despite the 
first description of acupuncture by a western physician having occurred earlier on 
the 13h century, its adoption in Europe is recorded as started subtly and much 
later, only on the 17th century.
As previously stated regarding the subject of TCM, also when it comes to 
acupuncture, some skepticism about its effectiveness still exists in our days, 
particularly in western countries, where TCM concepts are not as easily 
understood at the light of scientific rational approaches (World Health 
Organization 2002); (Kaptchuk 2002).
Over the last decades nonetheless, and particularly due to several scientific 
advances in acupuncture research, the WHO (2002) concluded that there was 
sufficient data to support its usage for several medical conditions, and its 
adoption is spreading amongst many western medicine practitioners (Haake, 
MüLler et al. 2007); (Lee, Shin et al. 2009); (Cheung 2011); (Zhang, Wu et al. 
2014).
3.3.1
Acupuncture Mechanism
The therapeutical approach of Chinese Medicine encompasses the correction of 
imbalances between Yin and Yang, Qi and the phases. Within this vast picture, 
acupuncture is applied to reestablish disharmonies via corrective regulatory 
mechanisms.
The United States Department of Health and Human Services, through its National 
Centre for Complementary and Alternative Medicine (NCCAM), defines 
acupuncture as a family of procedures designed to stimulate specific points in the 
38 |114
body, using a variety of techniques (NIH: National Center for Complementary and 
Alternative Medicine (NCCAM) 2006).
According to Porkert et al. (1999), these points may be classified into three 
categories: 
-points within locations exhibiting is increased sensitivity, in reaction to some 
local disease, called ashixue, used for direct, localized and symptomatic 
treatment; 
-points that due to their precise anatomical topology can be located in any 
individual, confined to the outside of the conduit system, or extracardinal 
foramina; 
-points of precise topological location, that besides therapeutical function, also 
have diagnostic significance, called cardinal foramina.
Each conduit is connected to a specific organ or viscera and as such, a conduit 
acts as an extension of a specific body part, organ, or region. This explains why 
external factors may influence inner organs and why disturbances at the body 
level might be felt in extimal layers, namely at those specific acupoints.
Acupuncture therapy is also described by some as a kind of reflexology - a 
regulatory system based on the fact that reciprocal reflexes exists between the 
Central Nervous System and different parts of the body forming an reflex arc, 
according to which, exterior stimuli at given receptors flow through afferent 
nerves into reflex centers, generating responses via efferent pathways, which 
would explain  acupuncture’s neural mechanism (Karavis 1997); (Jin, Jin et al. 
2007); (Langevin 2008). Researchers have also focused their attention on 
acupuncture’s mechanism at a humoral level, namely on its capacity to modulate 
neuro-immune responses and pain (Han 2004); (Ding, Hong et al. 2013). 
Acupuncture has in fact been proven to modulate the release of humoral factors 
such as opiate-similar substances and some neurotransmitters, like endorphins 
and encephalins (Jin, Jin et al. 2007). To this neural and humoral mechanism 
Greten (2011) adds an energetic mechanism.
In this sense, an acupoint represents a location in which stimulation or de-
stimulation may be imposed by the therapist or physician, in order to attain a 
specific regulatory effect on the body’s physiology.
Three distinct mechanisms of acupuncture have been described regarding 
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nociception: Peripheral, Spinal and Supraspinal.
The peripheral mechanism is explained on the basis of an axon reflex, where 
neuropeptides like substance P and calcitonin gene-related peptide are released 
from afferent nerves producing local vasodilation, modulating immune responses 
and assisting healing processes. The spinal mechanism, also referred as 
segmental mechanism, proposes that within tissues that share innervation with a 
specific spinal chord level, dorsal horn neurons may be inhibited by acupuncture 
via gate control. Depending on the needling technique, sympathetic or 
parasympathetic activity is affectedi. Regarding supraspinal mechanism, it refers 
to the neuronal structures affected by acupuncture, capable of activating 
descending inhibitory pathways like the Diffuse Noxious Inhibitory Controls 
(DNIC), neurohormonal responses or beta-endorphin mediated descending pain 
inhibitory pathways from the hypothalamus (Longbottom 2010).
Placing a needle in a specific acupoint is therefore believed to exert several 
actions at both local, regional and general levels. A local sensory stimulation may 
result in presence and synthesis of opioids, histamine, substance P, etc., whereas 
at regional level, it might result on the activation of dermatomes via reflex arches 
and at general level, the activation of the brain central mechanism of homeostasis 
via its autonomic system (Karavis 1997). Practitioners will choose a specific 
acupoint or an acupoints combination, to achieve the desired effect. Naturally, 
this statement implies that acupuncture has a regulatory direction, and in fact, 
according to some, the technique is able to revert physiological functions to a 
state of normality, although within certain limits - “if a patient is severely 
diseased, or suffering from a serious organic disease, it will be very difficult to be 
cured by acupuncture alone” (Jin, Jin et al. 2007).
3.3.2
Microsystems Acupuncture
In the last decades, TCM arsenal has been amplified by several investigators and 
investigations, leading to the development of new models of acupuncture. Based 
on the discovery of specific reflexive somatotopic fields within human anatomy, 
Microsystems Acupuncture are the perfect example of this broadening of the 
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i High-intensity needling may immediately increase sympathetic outflow to tissues supplied by the segment, followed by a decrease in outflow, 
whereas a low-intensity input could reduce sympathetic outflow in the segment
spectrum of TCM (Hecker and Steveling 2006).
Following the work of the French clinician Paul Nogier on the development of the 
acupuncture system of the ear, Ralph Alan Dale was the first to introduce the 
term Microsystems Acupuncture at the 1974 World Symposium on Acupuncture 
and Chinese Medicine. 
According to his definition, MAi was a formal expression of the entire’s body’s Qi 
in each major anatomical region. Having identified reflex systems in the ear, foot, 
hand, scalp, nose, iris, teeth, tongue, abdomen, back and every long bone, Dale 
proposed that each of these areas acted as a regional microcosmos, emulating an 
holographic anatomical arrangement of the whole body as well as its energies, 
where neurological, diagnostic and therapeutic reflexes, could serve the purpose 
of correcting pre diagnosed imbalances.
Bouevitch (2003) alleges that Microsystems of Acupuncture theory follows the 
principle of fractalization, or similarity. Merely from a physics point-of-view, 
fractals support scientific explanations of events, not only in the scope of MA, but 
also in several other Chinese Medicine concepts, such as the pathways of Qi flow 
(the conduits) and even acupoints. Fractal theory may also contribute to the 
explanation of conduits as wave formations, analogous to informational 
exchange systems occurring between the interior of a human body and its 
external environment.
In a general sense, Acupuncture Microsystems are homeostats - cybernetic 
models that allow information exchange between intimal organs and the extimal 
environment in order to maintain physiological equilibrium (Bouevitch 2003); 
(Hecker and Steveling 2006).
Similarly to the Fractals theory, another hypothesis for the explanation of these 
systems comes from biology. The theory of Embryo Containing Information of the 
Whole Organism (ECIWO) considers the human organism a living mosaic, where 
each unit contains information of the whole - an inborn embryonic feature where 
each and every cell is totipotential.  According to Schjelderup’s (1995) point of 
view this theory explains bio-holographic systems of acupuncture, such as ear 
acupuncture or foot reflexology, by which various organs and anatomical parts 
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i MA - Microsystems Acupuncture
are reflected in smaller areas of a circumscribed part of the body, and a stimuli in 
one of these prescribed acupoints develops an effect on the predetermined body 
part or organ. 
Popular accepted modern acupuncture microsystems include Ear Acupuncture, 
Scalp Acupuncture, Hand Acupuncture, among others, all of them sharing the 
same property of projecting body parts and internal organs within a specific 
boundary limited section of the skin, a kind of cartographic maps, where special 
connections between points and correlated organs and systems exists. 
Different systems reveal organizational variations: within Ear Acupuncture, there 
is a complete representation of organs with correspondent points and areas; in 
Korean Hand Acupuncture, there is a mini scale representation of channels in a 
very condensed space (hand); in Yamamoto’s Scalp Acupuncture we find a 12 
point representation of the 12 main channels found in regular acupuncture; in 
Oral Acupuncture the system offers punctual representation of coupled paired 
channels of the five phases seen in the classic TCM theory (Hecker and Steveling 
2006).
Curiously, MA had been already observed in the spectrum of regular 
acupuncture, although not immediately identified as such. In order to illustrate 
this statement Porkert (1999) stresses the importance of the back SHUi points, 
which represent in fact, the 12 main conduits where the functional activity of the 
body can be assessed.
Bouevitch (2003) believes that one of the advantage of these systems relies both 
on their ability to concentrate information in a limited surface and also on the 
fact that the total number of Microsystems is unlimited, providing huge 
possibilities of treatment from a single diagnosed condition. 
42 |114
i These dorsal inductories are special points located on the bladder conduit, where maximal manifestation of activity of the 12 orbs emerge, allowing 
a functional representation of the whole activity of the body
3.3.2.1
Scalp Acupuncture
Scalp Acupuncture (SA), as already noted in the previous chapter, belongs to the 
array of Acupuncture Microsystems. According to Scalp Acupuncture theory, 
treatment zones associated with body anatomy and their related functional 
capacities are mapped into the scalp. 
Needles are inserted within the thin layer of tissue beneath the surface of the 
skull, to a depth of a maximum of 1/2cuni with stimulation occurring in a variety 
of manners such as pulling/thrusting, twirling or electro-stimulation 
(Dharmananda and Vickers 2000).
Although Chinese Scalp Acupuncture dates back to early ancient China, the 
majority of the approaches to this technique were developed only in the mid 20th 
century, when notions of classic acupuncture and TCM were combined with 
prominent findings in the field of neurophysiology, neuroanatomy and bio-
holographic theory. Albeit classical acupuncture also uses head acupoints, SA is 
considered a different system of acupuncture whose foundations rely on a 
specific theory of human body somatotopy.
Initial acupuncture mapping of the scalp is attributed by some to the work of 
Huang Xuelong in the mid thirties. It is common belief that the physician started 
by theorizing the concept of the existing relationships between certain areas of 
the scalp and the cerebral cortex, with results pointing to effective treatment of 
brain diseases (Dharmananda and Vickers 2000); (Yamamoto 2003).
From the several existing Scalp Acupuncture systems, five are amongst the most 
known worldwide: 
Jiao’s Head Acupuncture - based on scalp zones corresponding to motor and 
sensory locations of the cerebral cortex; 
Fang’s Scalp Acupuncture - based on superimposed pictures of the spine and 
the human body [homunculus] in a prone position on the scalp, emphasizing 
speech and memory centers; 
Tang’s Head Acupuncture - which combines functions of the cerebral cortex and 
TCM theory of Zang Fu organs; 
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i The cun is a measure based on the patients body size and 1/2 cun corresponds to about 0,3 to 0,5 inches in a standard adult
Zang’s Treatment - mainly used in nervous and mental diseases;
Zhu’s Scalp Acupuncture - introducing the concept of therapeutic lines, based 
on TCM theory of Zang Fu organs and conduits, where four areas are mapped and 
needle manipulation is characterized by small amplitude lifting and thrusting, 
accompanied by massage of the respective body part being treated.  
Many of the existing Traditional Scalp Acupuncture systems were focused on the 
capacity to influence the brain’s motor centers and the locations to prick were 
selected according to the representative area of the actual function developed on 
the cerebral cortex. It wasn’t until the seventies, though, that one of the most 
popular modern scalp acupuncture systems was developed. Japanese 
anesthesiologist Yamamoto, took SA to the level of a complete acupuncture 
system. Yamamoto New Scalp Acupuncture (YNSA) (1989) differs from these later 
classical systems, because it considers an actual MAi somatotope on the skull, 
where all of the human body is roughly represented along the hairline and thus, 
the points chosen do not necessarily associate with cortex nerve centres .
The proliferation of diverse MA systems, led, as expected, to an array of different 
methodologies and several nomenclature schemes. In 1989, the WHO Scientific 
Group (1991), in view of the progressive increase in acupuncture worldwide 
adoption, issued a proposal for the international harmonization of acupuncture 
nomenclature, among which, these Microsystems. Within this proposal, scalp 
acupuncture channels, where attributed an alphanumeric code - MS# - standing 
for Micro-System. 
Heidelberg Scalp Acupuncture
Following previous explanations, the Heidelberg Scalp Acupuncture (HSA) is a 
somatotopic Acupuncture Microsystem technique, developed on the basis of 
correlations between specific skull acupoints (the majority related to the Regensii 
conduit), physiological functions and anatomical regions.
Special functions are attributed to the Regens conduit, also called Leading 
Sinartery.  It is a Yang conduit, originated in the perineum and its primary branch 
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i Microsystems Acupuncture
ii Or, the <Governing Vessel> in international TCM nomenclature, one of the twelve extraordinary conduits that has no correspondence to any organ 
or viscera
ascends through the medial plane of the spine, entering the brain between the 
occipital and the atlas, at the point Rg16i . It then goes further up to the top of 
the skull, descending from the forehead to the basis of the nose at the philtrum 
and joining the tendinomuscular conduit of the Stomachal orb. On its secondary, 
more internal branch, despite having the same starting point - the perineum -, it 
ascends through an abdominal branch, going directly to the heart, then to the 
brain through the throat and finally to the centre of the eye (Porkert, Hempen et 
al. 1999); (Greten 2011, Greten 2012). This conduit is also connected to the 
Renal orb through the reticulares ii  system, exerting great influence over the 
body’s vital energy, or Qi primum. 
Stressing its importance as means to correct physiological imbalances, by 
resorting to this conduit, TCM physicians bring up energies from the Renal orb to 
the surface. The Renal orb and its counterpart, the Cardial orb, are of special 
importance when it comes to neurological diseases, and this fact may help to 
explain the physiological action of Heidelberg Scalp Acupuncture on brain 
diseases.
The reference point of HSA is called Sk0, and it is found on the skull surface from 
the interception of two imaginary lines going from: (1) the tip of the ear lobe and 
the vertex, going through the top of the skull, back to the other ear vertex and 
lobe; and a second line (2), going from the tip of the nose to the tip of the 
occiput. This point encounters correspondence with regular acupuncture point 
Rg20iii and serve as reference to find auxiliary neighboring points.
Rg20 is, if not the most, one of the most important points of the whole Regens 
conduit. Its name, acording to Porkert et al. (1999) and the HMCMiv, conventus 
omnium, is a mention to a point, or foramen, in which all conduits convene - a 
reference to a location where all Yang conduits of the body are reunited. The 
point’s described functions include the support of the Cardial orb, unclogging the 
opening of the senses, and the capacity to bring up Yang from the lower 
caloriumv. Stimulation of this point is also described by some as a means to 
ameliorate forgetfulness, one of the leading symptoms of Alzheimer’s Disease 
(Huang, Lai et al. 2007).
45 |114
i Governing Vessel acupoint - GV16
ii Secondary conduits
iii or GV20 in international nomenclature
iv Heidelberg Model of Chinese Medicine
v Reference to the anatomical location bellow the navel
3.4
TCM & NEUROLOGY
According to Chinese Medicine, Neurology, per se, as a subject of human 
physiology, doesn’t exist in the same sense, as for instance, Gastroenterology, 
Urology, Gynecology or other medical specialities within Western Medicine. Most 
neurologic vegetative functions are mentioned within the whole system of the 
orbs, the agents and the ALTi.
In view of this premise Greten (2011) quotes five theoretical considerations 
concerning neurologic aspects within TCM:
1. In the ambit of the HMTCMii, the mind is expressed as a semi-autonomous 
group of signs and symptoms related to general functions associated with the 
brain, hence, it is not considered even as an complete orbiii, but a paraorb - 
paraorbis cerebri - whose manifestation occurs within the Renal orb, in the phase 
Water. Vegetative functions such as memory, brain processing speed, velocity of 
thinking and awareness, are therefore included in this specific paraorb. 
2. In the system of the orbs, the Cardiac orb is the counterpart of the Renal orb. 
As a result, a part of these neurological functions, like the Sheniv emanate from 
the Cardiac orb. Hence, the paraorbis cerebri is therefore dependent of the Yin, 
as the Yin is depicted by the Renal orb and its counterpart, the Yang, is 
represented by the Shen, whose functions are dependant of the Cardiac orb. 
In this reasoning, if there is a structural damage to the Yin caused by factors like 
age, trauma, infections, or others, the Yang will also suffer from this imbalance, 
resulting in a disturbance of so called higher nervous functions - the Shen.
In order to understand this relation, lets consider the example of Dysarthria - 
According to TCM, in Dysarthria there is an imbalance in the control of the 
muscles of the tong and jaw, accompanied by difficulty in mental word finding. 
This is both a problem of the Cardiac orb with Shen disturbances (incoherent 
thoughts), and also a Renal orb problem (with a structural lesion of the speech 
area - paraorbis cerebri).
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i Algor Ladens Theory or Shan-Han-Lun
ii Heidelberg Model of Traditional Chinese Medicine
iii an orb is not an organ but an organ pattern
iv The concept of Shen comprise the ability to create mental presence, emotional associativity, coherence of speech, fluent fine motrics as well as the 
capacity to establish of a primary order of emotions
3. Renal and Cardiac orbs are antagonistic phases, counter-balancing each other 
functions. Any disturbance in this equilibrium is identified as a Cardio-Renal 
rapport problem. This observation explains how a deficient Water phase (the 
Renal orb), may lead to neurological signs, as the Yin isn’t able to balance the 
Yang (Yang in this case reads Shen).
4. The mathematical representation of the system of the phases is a sinus wave, 
with its upward movements where sympathetic functions prevail, and 
compensating downward movements, where parasympathetic autonomous 
nervous system prevails (Figure 1). If this upward movement is insufficient this 
might lead to lack of muscular power (the Hepatic orb) and lack of Xuei. This lack 
of Xue in turn, results in a lack of Qi, as Qi is obtained from Xue.
5. Finally, a regional lack of Xue, according to the application of the second 
guiding criteria of the diagnose from the HMTCM results in Algor and in this 
particular case, the therapeutical strategy should be addressed in line with the 
model of six stages - Algor Ladens Theoryii.
In accordance to the above postulates, the general focus of a Neurological 
treatment should be to strengthen the Renal and Cardiac orb (first and second 
considerations), open the Qi pathways between them in order to accomplish 
counter-regulation (third consideration), and support Xue and Qi (fourth and fifth 
consideration) (Greten 2011, Greten 2012). 
Other scholars follow a similar reasoning. Gongwang (2006), for instance, 
describes three possibilities concerning the origin of congenital dementia:
a. Deficiency of Liver and Kidney, case where symptoms include dizziness and 
tinnitus, lassitude, diminished intelligence, poor memory and impaired 
judgement;
b. Turbid phlegm blocking the orifices, case where the patient experiences 
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i Remember that the Xue in translated as the functional vegetative capacity bounded to body fluids with functions to nurture, moisten, warmth and 
bring Qi to the tissues - in western medicine this concept is similar to the effects of microcirculation and the blood
ii In classical TCM, the Shan Han Lun
diminished intelligence, distention and fulness of the abdomen, heavy saliva 
production and heaviness feeling in the head, lassitude, lack of hunger and 
presents dull eyes. The basis for this assumption b lies on the fact that Spleen 
deficiency causes dysfunctioni  in the ability to bring the clear up. Therefore, an 
insufficiency of spleen will result in stagnation occurring mainly in the middle 
caloric region (belonging to the Tricaloric orb), and lassitude, due to the fact that 
the Spleen is unable to bring the Yang up, or, in other words, unable to bring up 
the energy; 
c. Obstruction in collaterals conduits by stasis of blood. Again like other 
theories precluded, the normal function and nourishing effect of Xue is of 
foremost importance to avoid neurological diseases. In this particular case c, the 
symptoms encompass “dull spirit”, diminished intelligence, forgetfulness, 
incoherent speech, strange and erratic behavior, numbness of the limbs among 
others. This in all results in a treatment principle compelling the restoration of 
consciousness by unblocking the pathways, promotion of blood circulation by 
draining collateral conduit system, and supporting the Kidney. 
3.4.1
TCM on Dementia and Current State of the Art
Referring to the major subject ACUPUNCTURE, from 1991 to 2009, 3975 articles 
were published in 927 different journals. According to the Journal of Citation 
Reports™ the compiled output data on acupuncture research, falls into a total of 
117 subcategories, from which the top subjects include Neurosciences with a 
whooping 19%, and Clinical Neurology with 13%  (Lee, Shin et al. 2009).
This data might lead to the assumption that Brain diseases, Neurocognitive 
disorders including Dementia or Alzheimer would arouse more interest than they 
actually seem to do… In fact, at first glance the subject doesn’t even seems to be 
very exciting to investigators - a simple search on pubMedii, using the words 
“Dementia” AND “Acupuncture” reveals no more than 156 articles. When 
narrowing the search criteria to “Alzheimer” AND “Acupuncture”, that number 
diminishes to 71 results, and from these, only 55 use humans as experiment 
subjects.
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i The function of the spleen acording to TCM is associated with the capacity to extract nutrients from the food, turning digested food from the 
stomach into nutrients and Qi, promoting blood formation, assisting water metabolism and bringing the Yang “up”
ii The search was performed on 6/March/2014
Despite this modest values, on WHOi (2002) guidelines regarding the usage of 
acupuncture, in its section two (Diseases, symptoms or conditions for which the 
therapeutic effect of acupuncture has been shown but for which further proof is 
needed), we can read “Vascular Dementia”, as well as in other sections - 
“Depression” -, a symptom frequently seen in these patients. 
A review of Randomized Control Trials (RCT) from 17 databases until the year 
2008 to evaluate the efficacy of needle acupuncture in the treatment of 
Alzheimer’s Disease on Humans, only yielded 3 out of 40 articles that met the 
desired quality criteria, and all of them showed some type of shortcomings in 
terms of reported methods of randomization and allocation of subjects (Lee, Shin 
et al. 2009).
Even broadening the scope of the analysis to Dementia, a similar conclusion is 
supported by other reviewers (Peng, Wang et al. 2007). In the absence of quality 
randomized control trials, meta-analysis are scarce and inconclusive, suggesting 
the need for randomized double blinded placebo experiments. 
According to Han (2007), normal aging process can be explained by the abnormal 
function of the Tricaloric orbii. Chinese Medicine establishes that this specific orb, 
acts, first of all, as a pathway for the entering and exiting, ascending and 
descending of Qi. Secondly, that this orb is co-responsible for the production of 
this form of energy (Qi), essence (or Jingiii), blood and body fluids; and thirdly, 
that the normal activity of intimal orbs, (Liver, Heart, Spleen, Lung, Kidney and 
Pericardium), necessary to life activities, is dependent on the Qi activity on the 
Tricaloric orb. 
This author proposes the regulation of Qi activity within the Tricaloric orb as a 
conceivably good strategy to delay aging and prevent senile diseases. 
His proposed theory, entitled “Principle of Tonifiing Qi and Regulating Blood, 
Supporting the Root and Fostering the Source”, consists of using several 
acupuncture points, such as CV17, CV12, CV6, TE5, ST36, and SP10. The first 
three points would serve the purpose of regulating the upper, middle and lower 
caloric, TE5 is used as a means to regulate the whole Tricaloric orb, ST36 to 
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i World Health Organization
ii Triple Energiser in international nomenclature
iii Jing is defined by the HMTCM as the structive potential and its effects which are analogous to the effects of the nuclei of the cell, including 
donating the functional repertoire of the cell via DNA and reproductive functions, according to the Heidelberg Model of vegetative regulation
support the constitutional diagnosis and SP10 to supplement and harmonize the 
blood .
The understanding of the underlying mechanism by which acupuncture acts on 
neurological diseases is paramount to the development of an assertive 
therapeutical approach. Several researchers draw attention to the its effects and 
mechanism on mild cognitive impairment and Alzheimer’s disease (Guo, Shi et al. 
2002); (Zhou, Han et al. 2008); (Zhou and Jin 2008); (Feng, Bai et al. 2012); 
(Wang, Nie et al. 2012); (Zeng, Salvage et al. 2012); (Zhu, Guo et al. 2012);
(Sutalangka, Wattanathorn et al. 2013); (Zhang, Yu et al. 2013) ;(Liu and Fu 2014) 
(Sun, Luo et al. 2014).
Zhou & Jin (2008) analyzed various regions of the brain of Mild and Moderate AD 
diagnosed patients before and after acupuncture. In their study, twenty-six 
patients diagnosed with AD and a mean age of 71.6 years, were submitted to 
electroacupuncture interval stimulation on HT7, ST36, ST40 and KI3, while their 
brain was being scanned via fMRIi. 
Results showed both right and left brain hemisphere activations within areas 
related to cognition, contributing to support good evidences of the usage of 
acupuncture on AD patients and the possible mechanism by which these 
improvements occur.
Similar results where obtained by Zeng et al. (2012) Also recurring to functional 
brain images, the researchers were able to expose increases and decreases of 
activity prior to acupuncture, on areas are closely related to memory and 
cognition that usually present abnormal functional connectivity on patients with 
Mild Cognitive Impairment and AD, namely on the temporal and prefrontal lobe.
The principle of needle retaining had already been mentioned in the oldest 
medical book of Chinese Medicine - Yellow Emperor’s Inner Cannon. The benefits 
of this practice, called Acupoint Thread Embedding (ATE), are identified as both 
the potential to attain a more powerful effect as to maintain it for longer periods 
of time (Sun 2012).  
The technique was tested by Zhou et al. (2008) on AD patients using acupoints 
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i functional Magnetic Resonance Imaging
HT7, ST36, ST40 and KI3. ATE was performed once a moth for a total of 6 months 
on half the patients, whereas the other half received Sham acupuncture. 
By comparing scores of MMSE and ADAS-cog before and after treatment, 
correlation between fMRI and cognitive ability was assessed. The results showed a 
statistically significant improvement on MMSE score, when compared to the sham 
group and a statistically significant decrease on ADAS-cog, both evidences of 
cognitive improvement, further confirmed by fMRI observation of activations in 
frontal, temporal lobe, cerebellum and marginal system, supporting the beneficial 
effect of ATE on patients suffering from AD. 
In a recent study, Wang et al. (2012) found similar results using different 
acupoints than Zhou (Zhou, Han et al. 2008, Zhou and Jin 2008). These 
investigators compared brain fMRI images of Mild Cognitive Impairment (MCI) and 
AD diagnosed patients versus healthy controls, while puncturing KI3 and LI4. 
By analyzing data retrieved before, during and after acupuncture, Wang et al. 
found significant differences between the groups, with AD and MCI patients 
showing activations in regions consistent with brain function impairment, namely 
on temporal and frontal lobes, supporting the fact that the usage of these points 
may activate cognitive related brain areas. 
These results also con-substantiate those obtained on animal models, where 
specific acupoint stimulation is believed to cause trophic factor releasei, enhance 
cholinergic transmission, diminish apoptosis and oxidative damage and reduce A-
beta proteins in brain areas such as the hippocampus of these AD models (Zeng, 
Salvage et al. 2012). 
When reviewing the progress of experimental research on the therapy of AD 
using acupuncture, Liu & Fu (2014) summarized the mechanisms by which AD is 
treated in animal models. 
Their work points to several strategies, among which the reduction of beta-
amyloid protein, attenuation of phosphorylation of tau protein, regulation of 
neurotransmitter dysmetabolism and oxidative stress, reduction of neuron 
apoptosis, inhibition of glial cells differentiation, adjustment of G protein 
signaling transduction, and normalization of mitochondrial dysfunction. 
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i Trophic factors are responsible for the development of certain neurons within neural networks
A similar outcome had already been revisited by Zhu et al. (2012), on a review 
from which the authors preclude the need for syndrome differentiation when 
approaching acupuncture therapeutic strategy in order to clarify its mechanism 
on AD.
Zhang et al. (2013) resorted to Senile Accelerated Mice in order to analyze the 
effect of “Sanjiao Acupuncture Therapy” on hippocampal neuron loss and 
astrocytosis of glial cells. They concluded that the therapeutic strategy, 
consisting on the stimulation of CV17, CV12, CV6, ST36 and SP10, contributed 
decisively to reduce, or at least delay neuron loss, suppress astrocytosis and 
regulate the relation between neuron and astrocyte. 
The authors noted increases of cerebral blood perfusion, relating it to 
improvements in terms in spacial learning and memory of the test subjects, 
arguing that the augmented blood supply would therefore reduce the formation 
of reactive oxygen species, resulting in those measured cognitive improvements.
Following this previous work, Zhang, et al. (2014)  demonstrated the 
improvement of cognitive abilities among rats with Multi-Infact Dementia, 
shedding some light on a possible acupuncture neuroprotective effect over 
oxidative stress and chronic hypoperfusion of the brain (major risk factors in the 
development of dementia). 
After injecting beta Amyloid protein on the hippocampus of Wistar rats in order 
to develop suited AD models, Sun et al. (2014) tested the effects of acupuncture 
and moxibustion, on ultrastructure and Silent Information Regulator 1i, on 
hippocampal neuron mitochondria.
By using GV20 and BL23 acupoints and analyzing the results, the researchers 
found that within the acupuncture group, both the ultrastructure in hippocampal 
neuron mitochondria was improved, as also SIR1 increased, promoting the 
recovery of injured mitochondria.
In a complementary work, the same authors found that the proposed therapy was 
able to reduce over-expression of Abeta-binding alcohol dehydrogenaseii, 
therefore improving hippocampal neuron mitochondria energy metabolism. 
Once again, supporting the kidney, in this particular case, via acupoint BL23, 
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i Silent Information Regulator 1 is a histone deacetylase which has been reported as having neuroprotective effects on neurological diseases
ii An enzyme found in neuronal mitochondria, which increases molecular mitochondrial free radicals
seems to yield effective results in AD. 
Sutalangka et al. (2013) focused their research on the beneficial effect of laser 
acupuncture at acupoint HT7 on learning and memory function. 
Resorting to animal models, the authors started by inducing memory impairment 
via injection of a cholinotoxin in Wistar rats. Both Spacial Memory, levels of 
acetylcholinesterase (AChE), Superoxide Dismutase (SOD)i, Catalase (CAT)ii, 
malondialdehyde (MDA)iii, glutathione peroxidase (GSH-Px)iv were assessed at 
several time frames, to conclude that on the group receiving acupuncture, SOD 
and CAT significantly increased in the hippocampus but not MADv, suggesting 
that oxidative stress balance may not be so important in this cognitive enhancing 
effect. Despite this fact, AChEvi activity within the hippocampus was suppressed, 
thus increasing the concentration of AChvii. The authors suggest that laser 
acupuncture at Ht7 leads to improvement in cholinergic function which in turn 
results in reduction of cognitive impairment within these AD animal models.
Fang et al. (Fang, Zhu et al. 2013) suggested the improvement of AD by 
electroacupuncture, via reduction of inflammatory reactions within the 
hippocampus and frontal lobe brain tissues. By submitting AD induced rats to 
electroacupuncture (EA) on acupoints GV20, KI3 and ST36 and comparing 
IL-1beta mRNA and P 38 MAPKviii protein expression levels in the hippocampus 
and frontal lobe amongst EA and sham groups, the investigators were able to 
demonstrate significative reduction of the over-expression of both substances in 
the first group, leading to the confirmation of the hypothesis that AD 
improvement occurs by reduction of inflammatory processes in the brain. 
Using functional imaging techniques (PET ix and SPECx), Huang, et al. (2007) 
evaluated the effects of blood perfusion in several areas of the brain, and by 
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i SOD is an enzime found in living organisms, responsible for the removal of free radicals, therefore preventing cell damage
ii CAT is also an enzime found in living organisms responsible for the removal of the toxic hydrogen peroxide
iii Biological marker for oxidative stress
iv GSH-Px is an enzyme with oxidative damage protective effects
v Mitochondria-associated Degradation
vi Acetylcholinesterase
vii  Acetylcholine
viii P38 is a Mitogen-Activated Protein kinase involved in stress reactions like cell differentiation, cell apoptosis and autophagic reactions, whereas 
IL-1beta is a mediator of the inflammatory cascade, also involved in cell differentiation and apoptosis
ix PET- Positron Computerized Tomography
x SPEC - Single Photon Emission Computerized Tomography
semi-quantitatively analysis, the changes of blood glucose metabolism, resulting 
from needling a specific combination of acupoints on Vascular Dementia patients. 
The points chosen by the team included LI15, LI11, TE5, LI4, SP10, ST36, SP6, 
HT3, plus other three points, pricked individually and in combination - GV20, 
GV26, HT7.
Interpolating the results obtained from MMSEi, ADLii and FAQiii and the outcome 
of the imaging techniques and glucose metabolism, they aimed to understand the 
differences and specificity of using those three additional points (GV20, GV26, 
and HT7). 
Although these authors deliberately excluded patients with Alzheimer’s Disease, 
the results may yet be important to the present study, since they might shed 
some light on the therapeutic strategy to pursue as well as the acupuncture 
mechanism underlying acupuncture usage in Dementia. 
The investigators proved that needling those three additional acupoints, showed 
several benefits in patients with Vascular Dementia, with diverse functional 
directions: the tests performed using GV20 showed more pronounced effect on 
temporal lobe, diencephalon and prefrontal cortical system, prone to improve 
memory and executive capacity; with GV26 the effect was more towards the 
prefrontal cortical system, enhancing executive capacity, and when combining 
conventional therapy with HT7, the effect was similar to the one obtained with 
GV20, although weaker in power. 
The study concludes that combing the three namely acupoints, could positively 
influence multiple nervous system functions related with cognition and 
intelligence on Vascular Dementia patients.
Resorting to fMRI to identify abnormal connectivity areas of the brain, among 
patients diagnosed with MCIiv and Healthy Controls (HC), Feng et al. (2012) tested 
the effects of Deep Acupuncture (DA) versus Superficial Acupuncture (SA) on KI3. 
Following previous investigations, the authors found abnormal connectivity in 
regions related to memory within the MCI group in the resting state, namely in 
the temporal area (hippocampus, thalamus, fusiform gyrus) and prefrontal 
cortex. 
When comparing DA and SA, results suggest that acupuncture is able to modulate 
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i Mini Mental State Examination
ii Activities of Daily Living
iii Family Attitude Questionnaire
iv Mild Cognitive Impaired
abnormal region’s connectivity within MCI patients, with this effect being 
stronger when using DA needling. 
Lombardo et al. (2001) studied the effects of acupuncture on the treatment of 
depression and anxiety in patients with Alzheimer Disease (AD) and Vascular 
Dementia (VD). 
Eleven patients, with a mean combined age of 76 years and mean MMSE scores of 
22.4, ten diagnosed with AD and one with VD, were evaluated after a minimum of 
22 acupuncture treatments chosen accordingly to six diagnostic categories of 
TCM. Used points included GV20, KI3, ST36, Sishecongi, Yintangii, SP6, HT7, GB9 
and GV23 and measures of assessment included the Cornell Scale for Depression 
in Dementia (CSDD), the Speilberger State Anxiety Inventory, and the Mini-Mental 
Status Examination.
The results yielded significative improvements in all of the Anxiety scales used, 
but regarding Depression, only on CSDD the differences were statistically 
significant. Despite the fact that cognitive function had not been tested, some 
caregivers reported improvements in the subjects thinking abilities, maybe 
indicating a close relationship between cognitive ability, anxiety and depression. 
In another study, designed to evaluate the effects of acupuncture on AD, eight 
patients categorized according to TCM diagnostic criteria for Alzheimer’s Disease 
and MMSE scores, achieved higher rates on the respective neurocognitive scale, 
after being submitted to acupuncture on Sishecong, HT7 and KI3 bilaterally, on a 
seven day treatment cycle, after a total of 30 days, indicating a significative 
improvement of cognitive function (Kao, Wang et al. 2000).
Guo et al. (2002), tested the effects of Transcutaneous Electrical Nerve 
Stimulation (TENS) on cognitive function and short-term memory in patients with 
AD. 
In previous studies using this technique, it had been suggested that TENS could 
possibly activate the hippocampus and hypothalamus. 
Guo and its colleagues set the electrodes on BL1, an acupoint believed to enhance 
the effect of ACh. Fourteen elderlies diagnosed with mild and severe AD, with 
mean age 77.2 years were subjected to TENS every other day for a total of four 
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i Name atributed to a combination of 4 points located 1 cun anterior, posterior and lateral of GV20
ii Extra point located in the course of the Gorverning Vessel conduit, between the eyebrows
weeks. 
The cognitive function was measured via the revised Hasegawa’s Dementia Scale 
(HDS-R), and short term memory via a seven picture test (SMT-7) designed by the 
research team. The neurocognitive test (HDS-R) was performed before and after 
the treatments, and also 6 months prior to its end in order to assess long-term 
effects. Results depicted significative improvements on HDS-R and SMT-7, 
specially on mild AD diagnosed patients after the fourth week treatment, but they 
were not held after the six month period. 
About the effectiveness of scalp acupuncture
In the past, typical uses of Scalp acupuncture were closely related to cerebral and 
neurological diseases, due to the specific location of acupoints in manifold areas 
of the brain (Dharmananda and Vickers 2000). This restrictive focus of the usage 
of SAi to nervous system disorders is still prevailing among several practitioners, 
although in later years this spectrum has been broadly increased to incorporate 
several other diseases besides those related to the brain.
Randomized Control Trials of SA for Acute Hypertensive Intracerebral 
Hemorrhage were reviewed by Zheng (2011). Although no scientific evidence was 
found in regard to the outcome of death or dependency at the end of long-term 
follow-up (3 months), in patients who survived, the authors found improvements 
on the recovery of the neurological deterioration presented as a consequence of 
the disease. 
Lee et al. (2013) compared the efficacy of known SA models versus conventional 
therapies (pharmacological, physical and deep brain stimulation) on Parkinson’s 
Disease (PD). Yielding a total of 185 Parkinson’s Disease patients, the researchers 
concluded that albeit not entirely convincingly, (mainly due to methodology 
issues), effects of SA on PD seemed a promising valid therapeutical approach. 
In a pilot study, Allam  and his peers (2008) compared the efficacy of combined 
Scalp Acupunture and Language Therapy (LT) vs Language Therapy alone in 20 
Autistic children, to show superior significant improvements in cognitive 
function, attention as well as in expressive language on the combination test 
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i Scalp Acupuncture
group. Both Yamamoto New Scalp Acupuncture (two needles - cerebrum and 
aphasia acupoints), temple zone acupuncture (two needles) and three classical 
acupuncture points were used - GV20, GV26 and GV17. The needles were 
retained in place for 20 minutes, on a twice a week basis regimen for two 
months, followed by another two months rest with a total of nine months 
experimental duration. 
Patients suffering from Dementia also seem to benefit from SA. Investigators 
showed marked improvements in terms of the cognitive deficit measured by the 
Mini Mental State Examination test, on mild to moderate Dementia patients 
subjected to electric scalp acupuncture stimulation when compared to body 
acupuncture (Huang, An et al. 2012).
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The effects of acupuncture in AD are not uncontroversial, with some authors arguing that poor 
results and confounding investigations are the result of a generalized lack of scientific quality. 
Randomized Control Trials within this particular subject are scarce, and just a few of those have cut 
clear methodologies or even sufficient patients to guaranty scientific validity (Ernst 2006); (Lee, Shin 
et al. 2009). 
Despite that fact, some results and clinical experience are encouraging enough to lead new 
investigations in this area. 
Although there is no cure for Alzheimer’s Disease, research shows that both Western Medicine 
pharmacology, as well as Traditional Chinese Medicine, may improve the outcomes of the disease by  
reducing the magnitude of the impairments that come with the rather complicated pathology, thus 
delaying the patients loss in terms of quality of life.
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Arguments
Pharmacological treatment in Alzheimer’s Disease is still somewhat 
unsatisfactory. Science hasn’t yet found a way to revert the symptoms, and 
particularly in more advanced stages of the disease, the overall therapeutical 
benefits are not sufficient for these patients to live an autonomous life and 
perform their daily activities on an individual basis.
As the literature review shows, acupuncture has already exhibited some positive 
effects on AD animal models and patients, however, human clinical trials are yet 
scarce and those that are published, usually rely on small sized samples.
Studies on the subject of acupuncture for AD resorting to imaging techniques like 
fMRI, have definitely contributed to current state of the art by providing possible 
physiological explanations regarding the mechanisms of acupuncture in patients 
suffering from the disease.
To the best of our knowledge, no investigation on Heidelberg Scalp Acupuncture 
for Alzheimer’s Disease has been published. Given the neurobiological plausibility 
of SA effects and its positive clinical outcomes, it is also possible that the 
technique exhibits beneficial effects on Alzheimer’s Disease.
Objectives
a.To evaluate the effect of Heidelberg Scalp Acupuncture (HSA) on the cognitive 
function of Mild to Moderate Alzheimer’s Disease patients in a preliminary trial.
b.To assess the feasibility and effectiveness of the research protocol for a future 
clinical trial.
Expected Results
We expect that HSA positively contributes to improve cognitive function in 
patients with Alzheimer’s Disease, which being the case, might lay ground for a 
future multi-centric, randomized clinical trial, with a double-blinded controlled 
design. 
From previous research, it is also expected that these effects will be more 
pronounced among patients diagnosed with Mild to Moderate stages of the 
disease.
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If HSA shows good results, it may then be used by physicians as an additional 
therapeutic tool for the conventional treatment of Alzheimer’s Disease.
Research question
Does HSA improve cognitive function in Mild to Moderate AD medicated patients?
Study hypothesis
Are there any significative differences in cognitive function of Mild to Moderate 
AD diagnosed patients, when they are subjected to HSA in addition to their 
pharmacological therapy?
a-MMSE
H0a There is no statistical difference in the score of MMSE before and after HSA 
µDifferences=0
H1a There a statistical difference in the score of MMSE before and after HSA 
µDifferences≠0
b-ADAS-cog
H0b There is no statistical difference in the score of ADAS-cog before and after HSA 
µDifferences=0
H0b There is a statistical difference in the score of ADAS-cog before and after HSA 
µDifferences≠0
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Misericórdia, Marco de Canaveses.
Nuno Correia, MD
Specialist in Internal Medicine – Emergency Service, Hospital São João, Centro 
Hospitalar São João, Porto 
MSc in Traditional Chinese Medicine
Research supervision
Professor Henry Johannes Greten, PhD, MD
Director of the TCM Master Program – ICBAS-UP
Head of the Heidelberg School of Traditional Chinese Medicine; 
President of the German Society of Traditional Chinese Medicine (DGTCMii), 
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Co-Supervisor 1- Dr. Pedro Carneiro.
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5.2
PROCEDURE
5.2.1
Ethical Considerations, protection of Human subjects 
and assessment of safety
Ethical Considerations
All patients voluntarily decided to be a part of the present study. Participants 
were not given or promised any warranties regarding their heath after or during 
the study.
The study was conducted in accordance to the 1964 Helsinki Declaration and 
international standards of Good Clinical Practice requirements and it was granted 
approval from the Ethical Committee (EC) of Instituto de Ciências Biomédicas Abel 
Salazar - Universidade do Porto (Annex 1) and positive feedback from Hospital da 
Santa Casa da Misericórdia de Marco de Canaveses (Annex 2).
All participating subjects were provided a consent form, describing the study with 
precise information, in order to exert an informed decision about their 
participation in the investigation (Annex 3). 
In any case where the patient’s cognitive state was dubious regarding their 
judgement capacity, the consent and further explanations were presented to the 
families or legal surrogates.
Subjects and/or families were briefed about the goals, methods, objectives, and 
potential risks or discomforts, as well as that it was their right to decide to 
withdraw or discontinue the experiment at any moment during his/her 
participation. They were also notified that no prejudice would result in case of 
refusal to participate or withdrawal from the study.
No interference with clinical decisions occurred. Dr. Pedro Carneiro, as the 
patient’s clinician, was asked, if feasible, to avoid any changes in the patient’s 
current medication during the study time frame.
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The incidence of adverse effects of acupuncture in multiple studies is residual. 
Regarding this issue, subjects were asked about adverse experiences at each 
visit, defined as any unfavorable and unintended sign, symptom or disease 
temporally associated, (or not), with the use of the acupuncture treatments.
In any case, the trial would stop if the investigators believed that there was an 
unacceptable risk of serious adverse events.
Confidentiality
All data collected in the scope of the present study is confidential, and 
identification of participants was preserved at all moments. Data will only be 
maintained during the necessary time to produce the present paper.
 
Participants Exemption
No pre established agreement existed that obliges participants to take part in the 
study. Both patients and other participants were free, at any given moment, to 
abandon the investigation if this was their desire.
Financing and Conditions
This study is independent and as such, not financed by any institution. 
Participants were voluntarily a part of it, without any promise of financial or other 
form of compensation. 
The resulting costs of investigation were fully and solely supported by the 
investigator.
Conflicts of Interest
None of the individuals that were part of the present study was involved in any 
conflicting activity.
Authorizations
The present study started after granted approval from ICBAS-UP Ethical 
Committee (Annex 1), with positive feedback from Prof. Henry J. Greten, in the 
quality of research supervisor (Annex 4), Dr. Pedro Carneiro as co-investigator 
and Prof. Amélia Ferreira, institutional representative of Hospital da Santa Casa 
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de Marco de Canaveses (Annex 2).
5.2.2 
Intervention report
In order to retrieve preliminary data to serve the purpose of defining a future 
assertive methodological protocol, an initial batch of patients suffering from AD 
were screened.
Dr. Pedro Carneiro, as an independent Neurologist within HSCMMC, was asked to 
identify patients he thought might be interested in participating in the present 
study, after the assessment of the proposed eligibility criteria (Table 9).
Inclusion criteria Exclusion criteria
1-Male or female patients, 40 to 90 y.o., with 
confirmed diagnosis of Alzheimer’s Disease, 
Possible or Probable according to the 
diagnostic criteria of the  DSM-V and NINCDS-
ADRA (American Psychiatric Association - 
DSM-5 Task Force 2013) (McKhann, Drachman 
et al. 1984)
2-Neurocognitive MMSE test score between 10 
and 24 (moderate AD: 10-18; mild AD: 19-24)
3-Patients under stable pharmacological 
conventional treatment (> 3 weeks)
4-Informed consent signed by patient or legal 
substitute. 
1-Diagnosis of mixed Dementia and 
Alzheimer’s Disease, or other Dementia type 
besides Alzheimer
2-Previous brain lesions that may influence 
cognitive function.
3-Epilepsy or other neurological chronic 
disease.
4-Any acute disease
5-Unstable at-risk patient
6-Hematological disease
Table 9 - Eligibility criteriai
After granted authorization by the ICBAS-UP Ethical Committee (Annex 1), and 
HSCMMC (Annex 2), 14 patients were selected, from which data was collected 
regarding their age, gender, educational level as well as current stable medication 
for AD.
Patients were contacted by the main investigator, in order to evaluate their 
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i Given the reduced number of participants, as will be seen later on, the researchers agreed on accepting one patient with an initial MMSE score of 25 
points
availability and willingness to incorporate the study. 
All of these initial contacts took place by phone, and considering these patient’s 
health condition and age, whenever possible, conversation took place between 
the investigator and the patient’s caregiver.
The caregiver was, in most cases, a close relative to the patient, to whom the 
experiment was thoroughly explained. The investigator started by introducing 
himself as a researcher working in partnership with the patients’ neurologisti, and 
a referral was made to Hospital da Santa Casa da Misericórdia de Marco de 
Canaveses (HSCMMC). 
In some of the cases, the caregivers knew or remembered the patient’s doctor, 
and that being the case, they were immediately asked if they had the habit of 
accompanying the patient to his neurology appointments at the hospital - this 
served the purpose of diminishing initial reservations and easing the introduction 
of the experiment, given that in most cases, caregivers had already witnessed any  
form of neurocognitive test administration, which in turn allowed the investigator 
to state that part of the experiment was a common task, already familiar to the 
patient.
After surpassing this initial barrier, with the caregivers’ confidence level in the 
investigator a bit higher than before, we addressed the purpose of the 
investigation, and the subject of scalp acupuncture was introduced. The 
technique was explained, as well as the research goals and expected results.
If the caregiver agreed to address the patient regarding the investigation, they 
were told that every question or doubt would be answered in an up close 
personal interview, without any further obligation of the patient to take part in 
the present study. 
They were also assured that no cost was due in terms of the experimentii, and 
that there was no need to dislocate the patient - with their permission, the 
investigator would go to the patients’s house, and perform the experiment right 
there, in order to minimize disturbance in their daily routines. 
After receiving this information, several caregivers asked to be re-contacted after 
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i Dr. Pedro Carneiro
ii More than once we were asked about the cost of the intervention and the place where the caregiver should bring the patient to receive the 
“treatment”...
a day or two, in order to give them time to address the patient regarding the 
study.
Over the course of the second contact, impressions, arguments and refusal 
reasons were collected for further scrutiny (see Table 10). Within those that 
agreed to incorporate the study, or others, that despite not entirely convinced, 
allowed us to speak with the patient explaining them the experiment ourselves, 
we scheduled a time and day to perform a personal interview.
Table 10 - Patients recruitment and data before intervention
In these interviews that took place, patients and caregivers were present along 
with the investigator. 
Whenever the subject’s mobility was not an issue, we kindly asked for a quiet 
room to explain the experiment, which regardless of the request, resulted in 
some conversations occurring in the patients bedroom, with the patient lying in 
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bed.
The procedure was carefully explained once again, but this time the speech was 
deliberately directed to the patient.
If both caregiver and patient agreed to the experiment, informed consents were 
introduced and read out loud, before signed. 
Protocol Administration 
Points to prick during the preliminary study were suggested by Prof. Henry J. 
Greten, based on the Heidelberg Clinic of Chinese Medicine clinical expertise 
group treating Alzheimer’s Disease patients. 
Seven gold scalp acupuncture needles were placed on the patient’s skull, on the 
so called seven chakras area, starting by the reference point located at GV20i. 
From this point forward, six other needles were placed, on anterior direction, 
distant by 1 (one) Scalp Acupuncture cunii from the previous. The needles were 
then retained for a period of three days, after which they were removed and 
neurocognitive tests repeated.
-following the previous paragraph-
If the patient had available time at that first interview, the first part of the 
protocol was immediately applied - both MMSE and ADAS-cog were performed, 
and at the end, scalp acupuncture needles were put in place. If not, a future 
session was scheduled in order to initiate the procedure.
Whenever necessary, a picture of the patient scalp was taken and immediately 
shown to the patient, to reduce any awkward feeling (Picture 1). 
Subjects were also advised that no change in their regular daily habits was 
needed and that it might be normal to loose some needles during the three day 
trial. 
An A4 sized sheet of paper with the investigator phone number was left near the 
phone, in case the patient or the caregiver felt the need to report anything out of 
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i GV20 is obtained from the intersection of two imaginary lines going from: the first - the tip of the ear lobe and the vertex, through the top of the 
skull, back to the other ear vertex and lobe; and the second - from the tip of the nose to the tip of the occiput.
ii The cun is a relative measuring unit used in Traditional Chinese Medicine to accurately locate acupoints.
the ordinary, (or ordinary), until the next interview, three days later.
Picture 1 - Photos of placed needles on the patients’ skull after interview on day one
During the three days retaining period, any contacts, comments and impressions 
were collected for further analysis. On the third day, neurocognitive tests were 
repeated after needle removal and their scores were collected. Following the 
tests, a structured interview was initiated with the patient and the caregiver to 
retrieve any further impressions felt during test period. 
Every now and then, we were asked by the caregiver or the patient himself, if 
their conditioni was “better or worse”. - regarding this issue, no assumptions were 
made or told and any remaining questions regarding that particular subject were 
redirected to the patient’s physician on a following appointment.
Before leaving, we gently recognized the patients’s and caregivers enrollment on 
the project, acknowledging their effort and emphasizing the major importance of 
their contribution. No contact was made ever since with any of the participants.
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i The questions posed relate to the AD condition, or the score of the test. “What do you think” or “Is he better?” or “Was there any improvement” [sic]
5.3
RESULTS
Six Alzheimer’s Disease patients, 4 female and 2 male, with mean age 78.5 years 
old, agreed to participate in the current preliminary study.
Out of the 14 inquired patients, more than half (8) refused to participate in the 
study. Objectively shared refusal reasons included patient’s fear from needles, 
lack of time to perform the intervention, inconvenient momentum i, hematological 
disease (eligibility criteria) and sudden acute disease (eligibility criteria).
From an subjective stand point - interpreted by the researcher although not 
objectively declared by the patients or caregivers -, at least two other reasons 
may be pin pointed: lack of confidence in the researcher or the procedure, due to 
inability of the researcher to clearly explain it over the phoneii and lack of 
previous knowledge of the experiment by the patients’ current neurologist.
Patients’ impressions and remarks on the study and any particular feelings that 
might have occurred during the test phase were registered, as well as results 
from Neurocognitive tests scores, performed previously and after the intervention 
(Table 11).
Descriptive statisticsiii are presented on Tables 12 to 16, considering a confidence 
interval of 95% (alpha = 0.05). 
Neurocognitive tests results
MMSE scores before the intervention ranged from 10 to 25 points with a mean  
value of 18.17 points, and after the intervention, between 19 to 26, with an 
average value of 22.00 points (Table 12).
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i One caregiver mentioned understanding the importance of the study, but at the present time he was too absorbed into taking care of his father, who 
was one of the Alzheimer’s Disease patient’s, her mother, who had recently lost her mobility while fighting to maintain the job he was about to loose, 
because of the time he spent everyday taking care of both. We think its important to detail this honest answer, which in fact, supports the thesis that 
caregivers face a huge burden dealing with the non immediate costs of the disease
ii All of the refusals occurred via the phone. In all of the cases when the investigator was given the chance to explain the procedure on a personal 
interview, the individuals accepted to take part of the study
iii Statistical analysis was performed resorting to statistical software IBM SPSSStatistics™ version 21
MMSE average score (points):
18.17 before => 22.00 after
ADAS-cog values before the intervention ranged between 18 to 43, with a mean 
value of 30 points, and after the intervention between 14 to 37 with an average 
value of 25.33 points (Table 13).
ADAS-cog average score (points)
30.00 before => 25.33 after
Normality adherence tests
Due to the small sample size (N=6), normality adherence tests were performed.
Normal distribution of MMSE and ADAS-cog is supported by the significance level 
of the Shapiro-Wilk test, which in both cases is superior to 0.05 (Tables 14 and 
15):
Shapiro-Wilk Sig. (MMSE_before) = 0.499 > 0.05 and Shapiro-Wilk Sig. (MMSE_after) = 0.213 > 0.05
Shapiro-Wilk Sig. (ADAS_before) = 0.248 > 0.05 and Shapiro-Wilk Sig. (ADAS_after) = 0.729 > 0.05
Table 14 - MMSE normality test
Table 15 - ADAS-cog normality test
The normality condition verified above, endorse’s the usage of Students-T test to 
compare mean scores obtained from MMSE and ADAS-cog scores.
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Table 12 - MMSE descriptive statistics
Table 13 - ADAS-cog descriptive statistics
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Mini Mental Status Examination
H0a There is no statistical difference in the score of MMSE before and after HSA 
µDifferences=0 or µMMSE_before-µMMSE_after=0
H1a There is a statistical difference in the score of MMSE before and after HSA 
µDifferences≠0 or µMMSE_before-µMMSE_after≠0
Table 16 - MMSE T-test statistics
The correlation analysis depicts a value of 0.712, but a significance level of 
0.112, higher than the alpha value (0.05), which doesn’t allow the rejection of the 
null hypothesis, meaning in this case, that the correlation is not significative.
Computing the results from the T-test for paired samples, we obtained a mean 
difference of -3.83 points (22.00-18.17), but again with a significance level (p-
value) higher than alpha - 0.084>0.05 - which once more, doesn’t allow the 
exclusion of the null hypothesis (H0a).
Therefore, the mean difference obtained (-3.833) is not statistically significative 
considering a 95% confidence interval.
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Alzheimer’s Disease Assessment Scale - cognitive sub-scale
H0b There is no statistical difference in the score of ADAS-cog before and after HSA 
µADAS_differences=0 or µADAS_before-µADAS_after=0
H0b There is a statistical difference in the score of ADAS-cog before and after HSA 
µADAS_differences≠0 or µADAS_before-µADAS_after≠0
Table 17 - ADAS-cog T-test statistics
The correlation obtained from the data is high (0.858), and the significance level 
is lower than 0.05, leading to the rejection of the null hypothesis - in other words, 
the correlation between the universe is not zero. 
The correlation is significative, and there is a positive linear association between 
the scores of ADAS-cog obtained on the two measuring moments.
Regarding the T-test analysis, the null hypothesis cannot be rejected. The mean 
difference is not significative considering a 95% confidence interval (p-value is 
higher than alpha (0.102>0.05)).
Sample size
Considering 90000 cases os Alzheimer in Portugal, considering a 5% margin of 
error and a 95% confidence level, we estimate a recommended sample size of 289 
cases.
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5.4
DISCUSSION
A thorough interpretation of the obtained results leads to several inferences and 
insights, addressed on the following paragraphs.
5.4.1
Challenges
The following topics epitomize several hindrances that should be taken into 
account on a following clinical trial:
 
Recruitment resistance
Insecurity must be pointed out as one possible cause of refusal to participate in 
the present study.
During the preliminary study and partially due to time restriction issues, the first 
contact with the participants was established by the main investigator. 
Our feeling was that part of the refusals to participate may be due to an absence 
of previous knowledge of the study from their current physician. Moreover, 
inviting subjects and explaining the intervention via the phone revealed to be a 
harsh task. Most of the patients are elderly people, many of them have hearing 
problems, (a big issue when explaining the experiment via phone) and their are 
not used to being contacted in order to participate in any studies whatsoeveri.
On a future project, first contact should be addressed by the patient’s physician, preferably 
during a regular appointment on an friendly environment, like the doctor’s office.
Personal interview increases the researcher’s chances of reducing or even eliminate 
insecurities, and broadcast a clearer message about the experiment we intend to perform and 
its vicissitudes.
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i As a peculiar note, we mention a specific case, where one of the patients whose wife agreed to incorporate the study, got cold feet hours before the 
first meeting. She called when we were already arriving at the patient’s house, stating that despite having agreed with the study, she was fearful that 
the investigator might go there, “break into her place and rob her” [sic]... We calmed her down assuring her that it was not the case, and that we 
didn’t intended to frighten her, but if we did and consequently she was insecure, with her permission and since we were already near her house, we 
would go there and explain the procedure once more and if then she still felt insecure, we would leave.
When we got there, we were being expected by two, very angry, fifty year old men, “defending” this lady.
After one and a half hours of talking, showing permission documents (from the Ethics Committee and the Hospital) and several phone calls later (to 
the hospital and the patient’s neurologist), we were granted authorization to conduct the interview. Even so, we were not able to be with the patient 
alone, and the tests were conducted in the presence of this (small) crowd.
Setting
At this preliminary study, after the patients recruitment, neurocognitive testing 
and needle administration took place in each of the patients’ house.
The procedures were performed at two separate moments. On the first moment, 
the subjects executed two neurocognitive tests and needles were applied, and on 
a second moment, needles were removed and tests were repeated. Each period, 
since we set foot on the patient’s house, through test administration and needle 
placing or removal, took about 60 to 90 minutes.
If going to the patient’s place is certainly more convenient to the subjects, who 
generally feel more comfortable within this kind of safe environment, just among 
these first batch, patients houses were occasionally 30 or 40km apart of each 
other, which made appointment scheduling a planning nightmare.
Moreover, some patients gently excused themselves from getting out of bed, and 
neurocognitive tests had to be performed with patients sometimes lying or seated 
in bed. If, for most cognitive domains evaluation this poses no problem, when it 
comes to Construction Drawing Capacity, subjects are asked to copy objects 
they’re shown within a piece of paper. Lying in bed against properly seated on a 
desk or table increases the probability of error within their drawings and 
therefore the probability of worse test results.
With this in mind, we recommend on further researches, resorting to specialized Alzheimer’s 
Diseasei nursing homes or Daycare Centers to recruit subjects. 
Within these institutions, subjects spend most of the time on daily interchangeable routines, 
making it easier to administer the tests in a much desired “safe environment”, thereby saving 
precious time. 
The fact that we had to travel from one house to another and repeat the procedure again and 
again between and within subjects, was a very “expensive” time consuming task.
Tests interference
As previously stated, within subjects houses, privacy was in some cases difficult 
to obtain.
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i Or at least Neurological Diseases nursing homes or daycare centers
Performing neurocognitive tests with family and relatives nearby, revealed itself 
to be a arduous task - some interviews had to be interrupted more than once, in 
order to advise caregivers that they shouldn’t try to help the patient. 
This was awkward considering two main reasons: for starters, the patient and 
caregiver have welcome the investigator within its house, and it is harsh to ask 
them to stand quiet and not interfere with the answers given by the patient a 
second time, when they had already been advised previously to the interview of 
the importance of getting unbiased test results; secondly, we understand that 
they did try to help the patient, with the best of intentions and it was funny to 
note that even after advised, some caregivers subtly positioned themselves out of 
the investigator’s eyesight, so that they could better help the patient without 
being noted.
Neurocognitive tests scoring
The outcome measure of the present study was cognitive function, evaluated by 
scores obtained from MMSE and ADAS-cog neurocognitive tests.
The reasons behind the choice of these particular tests were already explained on 
previous chapters, and supported by several authors like Rosen et al. (1984), 
Peña-Casanova (1997), Harrison et al. (2007), Chaves et al. (2011), among others, 
from which we emphasize the relatively fast administration time and ease of 
usage. 
Despite the fact that the generality of the tests questions’ have an objective 
scoring outcome, and by so, they remain easy to score i, others, particularly when 
it comes to ADAS-cog - have not -, demanding a meticulous analysis by 
experienced reviewers, which had already been noted by Peña-Casanova (1997).
To quote an example, we will consider question 9 - Oral Languageii from ADAS-
cog, where the reviewer is asked to valuate the quality of the patient’s speech and 
expression ability during the entire session (see table 18).
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i Pass the redundancy
ii The following is translated and adapted from the original - the tests were applied to Portuguese subjects and therefore, the portuguese version was 
applied
Question 9 - Oral Language
Valuation (points) Criteria
0 - No change (No change)
1 - Very Slight change One situation where the patient seems to demonstrate 
difficulty in expressing himself
2 - Slight Change The subject has difficulty between 25 and 50% of total session 
time
3 - Moderate Change The subject shows difficulty in over 50% of session time
4 - Moderately Severe Change Difficulty shown clearly in over 50% of session time
5 - Severe Change Mutism, the subject produces one or two words but the speech 
has void content
Table 18 - Adaptation of question 9 from the Alzheimer’s Disease Assessment Scale (GEECD 2007)
At first glance, and on an individual inquiry of one particular patient’s session, 
the valuation of question 9 doesn’t seem to arouse any subjective doubt, but as 
one patient is tested after the other, speech quality differences interpreted from 
previous tests, seem to become more or less apparent, meaning that experience 
with several patients is needed to properly quantify the degrees of speech 
impairment within AD patients.
In a future trial, it is recommended resorting to experienced psychologists concerning the 
administration and scoring of neurocognitive tests. In doing so we expected an increase in the 
precision of the test results. 
Also, it is undeniable that the investigator was cheering for better test scores on second 
interviews. Despite trying to be as objective as possible, we must admit the possibility of some 
bias having occurred. Therefore, combining experienced reviewers and a double blinded 
methodology, might result in more precise and unbiased outcome.
Study Compliance
During the three day trial period, patients were advised that needles could 
eventually fall during that time. 
One of the concerns expressed by the subjects and their caregivers regarding the 
experiment, was related to their personal hygiene - several patients asked if they 
were allowed to wash their hair, fearing that the needles would fall off, therefore 
ruining the study.
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Retaining the needles was in fact a requirement of the preliminary study, but 
patients were also told not to alter any of their daily routines, and as such, we 
didn’t intend them to neglect their personal hygiene.
On second interviews, some patients mentioned that needles, or part of them at 
least, had fallen. 
We could clearly understand by the speech of two caregivers (cases 2 and 3) that 
the actual needles hadn’t fallen, but they were removed by the patient in one case 
or by the caregiver, on the other.
On patient 2, the caregiver stated that all of the needles were removed due to the 
patient discomfort after day two. Nevertheless, this patient showed a 30% 
increase on MMSE score and an effective 11% improvement on the score of ADAS-
cog.
 
On patient 3, who had obtained worse results in both tests after day three, a 3% 
decrease in MMSE, and 3% increase in ADAS-cogi, the needles were removed right 
after the first day. We should also note that this patient was deep asleep when we 
arrived for the second interview, which might have influenced test results.
There was just one case were all the needles were retained until the end of the 
trial (patient 1). This patient improved in both tests - 27% on MMSE score (8 
points) and an effective 20% improvement on cognitive function measured by 
ADAS-cog (14 points). 
We know now, as reported by her daughter, that this lady new she was repeating 
the tests again in a near future and practiced some questions she still 
remembered from session 1, like word recall and word finding. 
Also on removal day, before the re-test, the caregiver reported several repetitive 
questioning from the patient, regarding which day of the week, month and year it 
was - questions that supposedly she also remembered we asked on the first 
session.
Naturally, at the present time and with retrieved data, there is no support to state 
whether pre-removal of the needles had or not an effect on test scores obtained 
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i An increase in ADAS-cog represents an increase in the magnitude of the cognitive impairment
at the end of day three. All patients except one, lost at least one needle during 
the experiment and even so, only in the case of patient 2 a decrease in cognitive 
function occurred (supported by both tests scores). 
Some questions raised by previous paragraphs include firstly, how important is it to retain the 
needles, or <all> the needles for a three day period, and secondly, whether those three days 
represent enough time to avoid bias on neurocognitive test performance due to patient’s 
memory recall of previously performed test.
On future trials, patient recruitment should consider a control group to which sham 
acupuncture is administered, and a wash out period in case of test repetition to avoid bias.
T-test results analysis
Regarding the applied neurocognitive testsi, an increase on MMSE points to an 
improvement on the patient’s cognitive function, as does a decrease in ADAS-cog 
score.
Stein et al. (2012), resorting to Reliable Change Indexii, found changes of 2 or 3 
points on MMSE, of enough magnitude to be considered reliable, indicating an 
effective cognitive change. On the present study, the computed average change 
was 3.83 points, indicating a possible positive effect. The same authors also 
found age and education to be highly influencing factors on MMSE scores. On the 
present study, only one of the six subjects had higher education, all of the 
remaining abandoned studies with about the age of nine. 
On a future trial, it is recommended to consider these (age and education level) as 
independent confounding variables, establishing subgroups and thus performing independent 
analysis.
Comparing these results with those obtained by testing cognitive function 
efficacy via pharmacological strategy, we observe that Birks (2009), for instance, 
found a 2 point statistically significant improvement on cognitive function 
measured on ADAS-cog scale, over the course of 26 weeks treatment with high 
Rivastigmine dosages on AD patients. Broadening the scope to include other Ach 
Inhibitors (Donepezil, Galantamine, along with Rivastigmine), the same author 
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i Mini Mental State Examination & Alzheimer’s Disease Assessment Scale
ii A test that determines what is considered a reliable change in test scores - unlikely to have occurred by error or bias
had already previously demonstrated improvements of [negative] 2.7 points on 
ADAS-cog over the course of 6 month treatments (Birks 2006). And similar results 
had also already been reported by Kaduszkiewicz et al. (2005). In this case, the 
investigator identified decreases of 1.5 up to 3.9 points on ADAS-cog with follow 
ups from 6 weeks up to three years, in AD patients submitted to cholinesterase 
inhibitors.
Despite some controversy regarding the usage of the MMSE, considered by some 
an inadequate instrument to detect small changes in cognitive function (Bowie, 
Branton et al. 1999), this scale is one of the most widely used for that purpose. 
Bowie et al. computed a true cognitive change in the order of a difference of a 
minimum of 3 points between observations.
When comparing researches on the efficacy of cognitive changes obtained 
resorting to Rivastigmine on 6-12mg daily dosages, measured by MMSE, Birks 
(2009) found improvements of about 0.8 points over the course of 6 months.
FDAi and EMEAii consider a change of 4 our more points in ADAS-cog score as 
representing a significant clinical effect on a clinical trial setting (McGleenon, 
Dynan et al. 1999). In the scope of this preliminary study, we observed changes 
of 2 up to -14 points in the 70 point ADAS-cog scale, with average score above 
that threshold (-4.67). On MMSE differences ranged from -1 up to 9 points.
Chronic effects of HSA were not analyzed over the course of the preliminary 
study, but considering the obtained results as an acute effect of HSA, MMSE 
scores increased in average 3.83 points, when comparing values obtained before 
and after the intervention. That represents an estimated 13% increase on the 30 
point test scale. On the other neurocognitive assessment tool, ADAS-cog scores 
decreased by a mean of 4.67 points, about 7% on the 70 point scale. 
Although measured changes of the scores in both tests denote a clear 
improvement in cognitive function, no statistical evidence was found. Putting 
aside (for now), methodology issues addressed above, it is our firm believe that 
one of the main reasons for absence of statistical evidence was the small sample 
size.
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i Food and Drug Administration
ii Nowadays European Medicines Agency (EMA) formerly know as the European Agency for the Evaluation of Medicinal Products
5.4.2
Proposed Methodology on a future clinical trial
5.4.2.1
Title
Effects of combined therapy (Heidelberg Scalp Acupuncture plus Pharmacological 
treatment) vs Pharmacological treatment on the cognitive function of Alzheimer’s 
Disease patients
5.4.2.2
Research Team (as in preliminary study)
Main investigator
Carlos Reis, Pharmacist
Degree in Pharmaceutical Sciences 
Specialist in Community Pharmacy
Master student in Traditional Chinese Medicine – ICBAS-UPi.
Co-investigators
Pedro Carneiro, MD
Specialist in Neurology - Hospital Santos Silva, Centro Hospitalar Vila Nova de 
Gaia/Espinho; Neurology Outpatient Clinic – Hospital da Santa Casa de 
Misericórdia, Marco de Canaveses.
Nuno Correia, MD
Specialist in Internal Medicine – Emergency Service, Hospital São João, Centro 
Hospitalar São João, Porto 
MSc in Traditional Chinese Medicine
Plus:
Psychologist 1
MSc in Clinic Neuropsychology, Hospital Da Santa Casa da Misericórdia de Marco 
de Canaveses
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i Instituto de Ciências Biomédicas Abel Salazar - Universidade do Porto
Psychologist 2
Centro de Dia para Pacientes de Alzheimer São João de Deus - Hospital Conde 
Ferreira
Research supervision
Main supervisor
Professor Henry Johannes Greten, PhD, MD
Director of the TCM Master Program – ICBAS-UP
Head of the Heidelberg School of Traditional Chinese Medicine; 
President of the German Society of Traditional Chinese Medicine (DGTCMi), 
Heidelberg, Germany.
Co-Supervisor 1- Pedro Carneiro (MD).
Co-Supervisor 2 - Nuno Correia (MD). 
5.4.2.3
Study Arguments, Objectives and Hypothesis
Arguments
Given the promising results found in the current preliminary study, it is our 
believe that HSA could have a positive effect on AD patients. 
On the previous study, due to several restrictions, we worked with a small sample 
of patients and we were given the chance to identify several methodological 
glitches.
In this proposed clinical trial, we take advantage of our current experience to 
improve methodology and carry on our previous research.
Objectives
To evaluate the efficacy of Heidelberg Scalp Acupuncture (HSA) on the cognitive 
function of Mild to Moderate Alzheimer’s Disease patients. This will be achieved 
by comparing the changes measured in ADAS-cog and MMSE, obtained from 
patients submitted to combination therapy (HSA plus regular pharmacological 
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i on the original - Deutsche Gesellschaft für TCM
therapy) versus patients performing regular pharmacological therapy.
Expected Results
As before, we expect that HSA positively contributes to improve cognitive 
function in patients with Alzheimer’s Disease. From previous research, it is also 
expected that these effects will be more pronounced among patients diagnosed 
with Mild to Moderate stages of the disease.
Research question
Are there any significative differences in cognitive function of Mild to Moderate 
AD diagnosed patients, when they are subjected to HSA in addition to their 
pharmacological therapy?
Study hypothesis
Experimental Group: subjected to HSA + Pharmacological therapy
Control Group: Pharmacological therapy
H0: There is no statistical difference in cognitive function between experimental 
and control groups
H1: There is a significative difference between cognitive function of experimental 
and control group
5.4.2.4
Setting
Pre Experimental Procedure - Recruitment and Design
Sample and Recruitment
This study will be focused on Portuguese individuals, with ages between 40 and 
90, diagnosed with Mild or Moderate stages of Alzheimer’s Disease.
Patients recruitment relay on an independent co-investigator approval, based on 
the patients clinical chart and eligibility criteria (table 8).
Regarding patient recruiting, we will resort to Nursing Homes and Specialized 
Alzheimer’s Daycare Centers. 
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At the present moment, after granted Ethical Committee approval, the project will 
be proposed to both Nursing Home da Santa Casa da Misericórdia de Marco de 
Canaveses and to the Centro de Dia para Pacientes de Alzheimer e outras 
Demências São João de Deus, belonging to Hospital Conde Ferreira. In the 
meanwhile, other institutions will be contacted in order to assess their 
availability.
AD diagnose is performed by Dr. Pedro Carneiro, Neurologist, and the 
neuropsychological tests administered with the cooperation of experienced 
psychologists. 
Inclusion criteria Exclusion criteria
1-Male or female patients, 40 to 90 y.o., with 
confirmed diagnosis of Alzheimer’s Disease, 
Possible or Probable according to the 
diagnostic criteria of the  DSM-V and NINCDS-
ADRA (American Psychiatric Association - 
DSM-5 Task Force 2013) (McKhann, Drachman 
et al. 1984)
2-Neurocognitive MMSE test score between 10 
and 24 (moderate AD: 10-18; mild AD: 19-24)
3-Patients under stable pharmacological 
conventional treatment (> 3 weeks)
4-Informed consent signed by patient or legal 
substitute. 
1-Diagnosis of mixed Dementia and 
Alzheimer’s Disease, or other Dementia type 
besides Alzheimer
2-Previous brain lesions that may influence 
cognitive function.
3-Epilepsy or other neurological chronic 
disease.
4-Any acute disease
5-Unstable at-risk patient
6-Hematological disease
Table 8 - Eligibility criteria
After the initial screening, potential participants are contacted, or when 
necessary, their families or caregivers to schedule an appointment in the 
presence of both the main investigator and the co-investigator. 
Within this initial interview, the general goals of the study are explained to the 
patient and family/caregiver, the procedures are scrutinized and any doubt is 
thoroughly clarified. Only then, the invitation for the patients to participate in the 
study is proposed, and on positive feedback, informed consents are presented.
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Sample size
Sample size was calculated based on previous preliminary study, resulting in a 
total of 289 subjects needed.
Sample randomization
After recruitment, a serial number based on the study’s entry date is attributed to 
each participant, and the sample is randomly divided into two groups using 
Excel™ random numbers function.
Outcome assessment
The primary outcome of the present study is Cognitive Function, measured by 
neurocognitive assessment toolsi. Reasons to support the choice of MMSE and 
ADAS-cog are, first of all, its validity and sensitivity to measure cognitive change, 
the existence of scientific literature to support its usage, their relative ease of 
usage (whether in terms of test administration and also completion time) and 
experience of the co-investigators in its application and scoring.
Administration and scoring of the neurocognitive tests will be performed by 
experienced psychologists.
Study design
The study design is a randomized, multi-centric, controlled, cross-over design 
(Figure 4).
The crossover design was chosen in order to reduce inter-individual variability 
when comparing control versus the experimental group, as well as to increase the 
number of cases. 
A three week wash-out period will be established to avoid carry over effects of 
HSA on the evaluation of the patients between intervention phases.
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i Referring to the US Food and Drug Administration, requirements needed for AD clinical drug trials efficacy assessment, are, first of all - improvement 
on a performance based cognitive instrument and second - proof that the improvement is clinically meaningful
Figure 4 – Experiment Design plan
Collected patients data
At Baseline (T0)
Name, Age, Gender, Educational Background, Time of Onset of the disease and 
Current Medication. 
At test period (T1 & T3)
Previously and after the three day intervention periods, neurocognitive tests were 
performed for each subject, and their outcome recorded.
During the experiment
At any given time during the experiment, drop off reasons, adverse effects as well 
as general feelings towards the procedure were collected.
Experimental procedure - Intervention
The experimental protocol is based on the clinical experience from the 
Heidelberg Clinic of Chinese Medicine workgroup, and on results from our 
preliminary study, concerning the treatment of AD patients with HSA.
As on the preliminary study, we again propose the placement of 7 semi-
permanent scalp acupuncture golden needles in the skull, within the area of the 
so called seven chakras and retaining them for a three day period.
Concerning the exact position of the needles, the reference point is located in the 
apex of the head, on the point described in literature as GV20, obtained from the 
intersection of two imaginary lines going from: the first - the tip of the ear lobe 
and the vertex, through the top of the skull, back to the other ear vertex and 
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lobe; and the second - from the tip of the nose to the tip of the occiput. Each of 
the six remaining needles were placed respectively one Scalp Acupuncture cun 
distant from the previous, in the direction of the forehead.
The actual needling will be performed by the main investigator under medical 
supervision, and no twisting, twirling, pulling or any other technique was applied 
to the needle until their removal in day 3, after which neurocognitive tests were 
repeated. 
While placing and removing the needles, patients should be comfortably seated in 
a resting chair, within an office gently provided by the respective hospital. 
In the cases where the needles fall during the test period, they were to be 
replaced as soon as noted. 
No other recommendation is made to the clinical staff regarding the patients 
daily routines, besides the fact to avoid any changes in their usual medication 
during the trial duration, if possible.
The experimental procedure is performed for the Experimental Group at T1, while 
at the same time, the remaining patients act as Control Group, and vice versa at 
T3.
A three week wash out period, (T2), was imposed between T1 and T3, with the 
objective to reduce any probability of occurrence of cognitive effects from 
previously administered procedures (figure 4).
Neurocognitive tests will be administered to every subject before and after 
intervention periods.
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6CONCLUSION
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“it depends, we have good days and some bad days, when he/she wakes up we’ll 
see”
Maybe eight out of ten times, this is the answer we get when you ask any 
caregiver or family member of an Alzheimer’s Disease patient [as we did] - How 
do you think he/she is progressing?
One of the key aspects of Alzheimer’s Disease is the progressive deterioration of 
both cognitive and non-cognitive functions. Brain activity and memory become 
more and more impaired as the disease progresses, corroborating the patient’s 
either suspicious or oblivious attitude towards life, categorically perceivable in 
later stages of the disease.
Diagnose is complex and definite verdict is only confirmed as a result of post-
mortem biopsy of brain tissue. Despite all the majestic scientific advances since 
its discovery in the turn of the 19th century, by the german psychiatrist Aloysius 
Alzheimer, there is actually no cure for AD. 
Therapeutic measures include any reasonable technique that might be used to 
improve the patient’s quality of life, granting any bit of the stollen autonomy the 
patient once had, usually encompassing neurocognitive stimulation and of 
course, the use of pharmacological agents. 
But within this intricate symptomatological picture, demential diseases are 
unforgiving pathologies, that even when resorting to any therapeutical weapon 
available, uncover real human life misery - if treating the cognitive deficit points 
to a well defined pharmacological class of drugs like acetylcholinesterase 
inhibitors, cerebral vascular dilating agents, or plain nootropics, the array of 
diverse symptoms that arouse with the disease, make these patients strong 
candidates for a “who takes more pills a day” contest. Hallucinations, agitation 
anxiety and emotional disturbances affect a huge percentage of AD patients, 
meaning that antipsychotics, anticonvulsants, antidepressants and anxiolytics are 
usual within these patients daily pharmacological schemes (Sink, Holden et al. 
2005), not to speak of medicines used to overcome common chronic elderly 
diseases like high blood pressure, diabetes, pulmonary obstructive diseases, 
among others.
Given this circumstances, comprising polimedicated elderly individuals with a 
somewhat feeble condition, neurocognitive testing demands rigorous scientific 
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design. 
In this sense, methodological glitches of this preliminary study, were pointed out 
in the previous chapters to the best of our observation. Larger, segmented 
samples are needed, preferably in a controlled testing setting.
Whether HSA acts by limiting the breakdown of acetylcholine, or by any other 
auxiliary mechanism such as the activation of functional brain connectivity areas, 
(as other investigators have demonstrated regarding acupuncture), or even 
increasing cerebral vascular perfusion, will remain an unsolved mystery after the 
present study and a challenge for future researching teams. However, in our 
moderate opinion, the increases measured in this preliminary study, are not to be 
neglected. 
Despite our failure to achieve proven scientific evidence, Heidelberg Scalp 
Acupuncture showed promising results on the reversion of the cognitive deficit 
felt by AD patients, demanding a new paradigm approach.
After these results, we expect to have raised in the scientific community, a little 
curiosity sparkle that leads to future and better designed clinical trials. 
If we can prove that Heidelberg Scalp Acupuncture has a significative effect on 
reverting the course of the disease, we would be positively contributing to a 
better life of those who suffer from a disease which has been growing 
exponentially over the last decades.
-Is there any greater challenge?
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Annex 3 - Informed Consent (pages 1 to 5)
Participação em Projecto de Investigação
Consentimento Informado, Livre e 
Esclarecido
Este modelo respeita a Declaração de Helsínquia1 e a Convenção de Oviedo2
Por favor, leia atentamente a seguinte informação.
Se achar que algo está incorreto ou que não está claro, não hesite em 
solicitar mais informações. 
Se concorda com a proposta que lhe foi feita, queira por favor assinar este 
documento.
Título do estudo
Estudo da eficácia da Terapia Combinada (Terapia Convencional Farmacológica + 
Craniopunctura) no tratamento da doença de Alzheimer
Enquadramento
O presente estudo é realizado como parte integrante da tese de Mestrado em Medicina 
Tradicional Chinesa de Carlos Miguel Soares dos Reis, ministrado pelo Instituto de Ciências 
Biomédicas Abel Salazar - Universidade do Porto.
A orientação do projecto cabe ao Exmo. Prof. Doutor Henry J. Greten – Professor do Mestrado 
de Medicina Tradicional Chinesa no Instituto de Ciências Biomédicas Abel Salazar - UP; Director 
Clínico do “Institute for Chinese Medicine”, Heidelberg, Alemanha, Especialista em Medicina 
Familiar, Naturopatia, Homeopatia e Acupunctura, pela Ordem dos Médicos, Alemanha, na 
qualidade de Orientador e ao Exmo. Sr. Dr. Pedro Carneiro, Médico especialista em Neurologia, 
na qualidade de Responsável Clínico.
Proposta
O projecto apresentado resulta de um trabalho de pesquisa e recolha de informação de 
investigações anteriores e o procedimento proposto foi pensado e simplificado por forma a causar 
o menor distúrbio possível nas rotinas diárias dos participantes. 
Em estrita coordenação com o Dr. Pedro Carneiro, propõe-se a pacientes diagnosticados com 
doença de Alzheimer, a adição de um protocolo de craniopunctura ao seu regime terapêutico 
habitual.
! 1|5
1 http://portal.arsnorte.min-saude.pt/portal/page/portal/ARSNorte/Comiss%C3%A3o%20de%20%C3%89tica/
Ficheiros/Declaracao_Helsinquia_2008.pdf
2 http://dre.pt/pdf1sdip/2001/01/002A00/00140036.pdf
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Explicação do estudo
O que é a acupunctura/craniopunctura?
A acupunctura é um ramo da Medicina Tradicional Chinesa e uma técnica terapêutica reconhecida 
pela Organização Mundial de Saúde (OMS) como Método de Tratamento Complementar, 
recomendada por esta Instituição para o tratamento de uma variedade de patologias entre as 
quais as Demências, da qual faz parte a Doença de Alzheimer.
Esta técnica, desenvolvida há mais de 3000 anos, consiste na aplicação de agulhas estéreis em 
determinados pontos localizados na superfície corporal, chamados de pontos de acupunctura ou 
acupontos. Quando esses pontos se localizam especificamente na zona da cabeça, toma o nome 
de craniopunctura.
[A acupunctura corresponde a uma técnica terapêutica amplamente utilizada no âmbito da Medicina 
Tradicional Chinesa, que consiste na aplicação de agulhas estéreis em determinados pontos localizados 
na superfície corporal.
A Craniopunctura é uma técnica de somatotopia, baseada num sistema de acupontos que estão 
funcionalmente correlacionados com regiões cerebrais. As agulhas utilizadas neste caso são semi 
permanentes, de 0,16mm de diâmetro por 3,4,5 ou 7mm de comprimento.
O procedimento é razoavelmente simples e a maioria dos pacientes não sentem desconforto salvo uma 
leve sensação de picada, que geralmente desaparece ao fim de alguns segundos.]
Qual o procedimento metodológico?
Caso autorize a participação neste projecto, o paciente será aleatoriamente englobado num de 
dois grupos experimentais, aos quais serão administrados protocolos de craniopunctura.
O protocolo consiste na inserção de agulhas de craniopunctura em zonas específicas do corpo.
Descrição cronológica do estudo
Antes de iniciar o protocolo experimental, irá proceder-se à recolha de dados referentes aos 
pacientes que acedam participar do estudo.
Posteriormente os pacientes serão aleatoriamente divididos em dois grupos.
A cada um desses grupos, irá administrar-se em período distinto, o respectivo protocolo 
experimental.
O protocolo consiste na aplicação de agulhas semi-permanentes de craniopunctura descritas 
acima, que deverão permanecer aplicadas durante um período de três dias. Antes e depois 
desta administração serão realizados os testes de avaliação neurocognitiva não invasivos.
Nenhuma outra alteração será efectuada na vida activa do paciente no âmbito do presente 
estudo, salvo as claramente explicitadas. Este continuará a ser acompanhado pelo seu médico 
responsável e a seguir as suas indicações terapêuticas.
Qual o local onde serão realizados os tratamentos?
O local onde se procederá à aplicação do protocolo, será aquele que mais convier às 
necessidades do paciente, responsabilizando-se o investigador por todas as deslocações que 
venham a ter lugar no âmbito do presente estudo.
! 2|5
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Quais são os riscos que posso esperar?
Quaisquer dos procedimentos descritos anteriormente, (acupunctura/craniopunctura), são 
razoavelmente simples e a maioria dos pacientes não sentem desconforto. Exceptua-se a 
inevitável a sensação de picada que advém da inserção da agulha, que geralmente desaparece 
ao fim de alguns segundos. Pode ocorrer um ligeiro sangramento na remoção das agulhas, 
considerado também normal.
Quanto tempo dura o estudo?
Está previsto uma duração aproximada de duas a três semanas para a realização do estudo. 
Um primeiro bloco decorrerá no espaço de três dias após a entrada dos pacientes para o estudo, 
após o qual se seguirá um período de wash out de uma semana, seguida de novo período de três 
dias para inverter os testes de sujeitos. 
Há garantias quanto ao resultado esperado?
O presente estudo está devidamente fundamentado noutras investigações científicas anteriores e 
propõe testar uma nova abordagem para o tratamento da condição patológica do paciente, mas 
como em qualquer estudo experimental, nenhuma garantia poderá ser dada ao paciente ou à sua 
família, quanto à resolução efectiva do problema de saúde.
Posso abandonar o estudo a qualquer momento?
Sim. 
Embora a sua participação seja fundamental para a nossa investigação, não há nenhum “vínculo” 
objectivo que obrigue o paciente a permanecer no estudo durante o seu período de realização.
Qual a importância da sua participação?
Ao participar neste estudo, estará a contribuir para o desenvolvimento da ciência nesta área do 
conhecimento.
Condições e financiamento
Este estudo não é financiado por qualquer instituição ou empresa, sendo os custos resultantes da 
sua produção, totalmente suportados pelo próprio investigador. 
A participação é de carácter voluntária e o estudo mereceu o parecer favorável da comissão de 
ética do ICBAS - UP e do seu orientador.
Qualquer ocorrência não prevista é, antes de mais, responsabilidade do investigador, e depois, da 
Escola de Medicina Chinesa de Heidelberg - Heidelberg School of Chinese Medicine -, sita em 
Karlsruher Straße 12, 69126 Heidelberg-Rohrbach, Alemanha, com os contactos telefónicos e 
electronico, respectivamente 06221-374546, heidelbergschool@aol.com.
Confidencialidade e anonimato
Os dados recolhidos no âmbito desta investigação são confidenciais, sendo em toda a altura 
preservado o anonimato dos seus participantes. Os dados serão mantidos unicamente durante o 
período necessário à realização da experiência e produção do documento de investigação.
Em meu nome, Carlos Miguel Soares dos Reis, agradeço de forma sincera a sua participação 
Assinatura: 
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Declaro ter lido e compreendido este documento, bem como as 
informações verbais que me foram fornecidas pela/s pessoas/s 
que acima assinam e que considero suficientes. 
Foi-me garantida a possibilidade de, em qualquer altura, recusar 
participar neste estudo sem qualquer tipo de consequências. 
Desta forma, aceito participar neste estudo e permito a utilização 
dos dados que de forma voluntária forneço, confiando em que 
apenas serão utilizados para esta investigação e nas garantias de 
confidencialidade e anonimato que me são dadas pelo 
investigador.
Utente: _____________________________________________________
Consentidor: ______________________________________________________
(Deverá anexar documento a atestar a representação legal do utente)
Data: __  /__  /_____
Assinatura: 
Este documento, composto de 5 página/s, é feito em duplicado - uma via para o/a investigador/a, 
outra para a pessoa que consente
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DECLARO, PARA OS DEVIDOS EFEITOS, QUE O PACIENTE 
REFERENCIADO NA PÁGINA ANTERIOR, ESTÁ LEGALMENTE A 
MEU CARGO.
Nome em caligrafia legível
_______________________________________________________
Assinatura
_______________________________________________________
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Annex 4 - Research supervisor feedback
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Prof. Doutor Henry J. Greten – Director do Mestrado em Medicina Tradicional Chinesa 
no Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto; Director 
Clínico do “Institute for Chinese Medicine”, Heidelberg, Alemanha, Especialista em 
Medicina Familiar, Naturopatia, Homeopatia e Acupunctura, pela Ordem dos Médicos, 
Alemanha, na qualidade de orientador de Carlos Miguel Soares dos Reis, declaro que  
concordo com os objetivos e metodologias propostas no âmbito do projeto “Estudo da 
eficácia da Terapia Combinada (Terapia Convencional Farmacológica + Acupunctura) 
no tratamento da doença de Alzheimer”.
.  
 
 
 
 
Porto, 4 de Abril   2014 
 
 
Orientador 
   Prof. Henry J Greten 
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